MGUS is a premalignant clonal plasma cell disorder characterized by a serum monoclonal protein < 3 g/dL, bone marrow plasma cells < 10%, and absence of end-organ damage attributable to the proliferative process.

Exam domain	One-glance essentials
Definition / diagnosis	*Premalignant monoclonal gammopathy: M-protein < 30 g/L, clonal BM plasma cells < 10%, no B-cell LPD and no clone-attributable organ damage* ^[1] Non-IgM, IgM and light-chain MGUS have different progression pathways ^[2]
Epidemiology / risks	*Common in older adults; prevalence rises markedly with age* ^[2] Overall progression risk is about 1%/year; higher risk with M-protein ≥1.5 g/dL, non-IgG isotype or abnormal FLC ratio ^[1]^[2]
Core mechanism	A small post-germinal-centre plasma-cell/lymphoplasmacytic clone produces one M-protein without sufficient burden for CRAB damage ^[2] Additional genetic hits and marrow-microenvironment changes drive progression to SMM/MM or WM ^[2]
Clinical picture	*By definition asymptomatic; usually an incidental M-spike, raised ESR or reversed A:G ratio* ^[1]^[2] Bone pain, anaemia, renal dysfunction, neuropathy or amyloid features require reclassification/workup, not reassurance ^[1]
Investigations	SPE/IFE + serum free light chains + urine electrophoresis/IFE characterise the clone ^[3] CBC, creatinine, ionised calcium and sensitive skeletal imaging exclude CRAB; BM confirms < 10% clonal cells ^[3] If amyloid suspected: tissue biopsy with Congo red ^[3]
Management	*MGUS itself: monitoring only—no anti-neoplastic therapy* ^[2] Repeat SPEP/FLC, CBC, calcium and creatinine at 6 months, then risk-adapted intervals ^[2] Clone-directed therapy is required if the protein causes MGRS, AL amyloidosis or clinically significant neuropathy ^[2]
Complications	Progression to MM/WM/lymphoma or AL amyloidosis ^[2] Immunoparesis/infection, fractures, VTE, anti-MAG neuropathy and paraprotein-related renal disease may occur ^[2] Lab interference can produce factitious hypercalcaemia ^[3]
Prevention / follow-up	Educate about red flags: new bone pain, fatigue/pallor, infection, foamy urine, neuropathy or oedema ^[2] Address bone health and age-appropriate influenza/pneumococcal vaccination; ensure standard VTE prophylaxis during high-risk periods ^[2]
Exam traps	*MGUS progression ≈1%/year; SMM ≈10%/year initially—a verified past-paper distinction ^[4] A small clone with renal/cardiac/neurological injury is not benign MGUS: think MGRS/AL amyloidosis ^[1] Check ionised calcium* when total calcium is high with paraproteinaemia ^[3]

References

^[1] Lecture slides: GC 030. An old man with bone pain and anaemia.pdf (MGUS definition and amyloidosis differential) ^[2] Senior notes: Ryan Ho Haemtology.pdf (Monoclonal Gammopathy of Undetermined Significance, Section 3.6.2) ^[3] Senior notes: Maksim Medicine Notes.pdf (monoclonal gammopathy workup and SLiM-CRAB) ^[4] Past papers: 2023 Fourth Summative MCQ.pdf (Question 44)

Monoclonal Gammopathy of Undetermined Significance (MGUS)

Monoclonal Gammopathy of Undetermined Significance (MGUS) is a premalignant clonal plasma cell (or lymphoplasmacytic) disorder characterised by the presence of a monoclonal immunoglobulin (M-protein / paraprotein) in the serum, without evidence of an underlying B-cell lymphoproliferative disorder and without end-organ damage.

Breaking down the name:

Monoclonal = derived from a single clone of B-lymphocytes / plasma cells (i.e., all the immunoglobulin molecules produced are identical)
Gammopathy = "gamma" refers to the gamma-globulin fraction on serum protein electrophoresis (where immunoglobulins migrate); "-pathy" = disease/disorder — so a disorder of the gamma-globulins
Undetermined Significance = we don't yet know whether this will remain benign or progress to a malignant condition; it is a state of clinical uncertainty

"MGUS refers to paraproteinaemia not related with underlying disease, e.g. MM/SMM, lymphoma, amyloidosis, WM" ^[2]

Key Conceptual Point

MGUS sits at the very beginning of the plasma cell dyscrasia spectrum. Think of it as the earliest, pre-symptomatic foothold of a clonal plasma cell population. The critical clinical question is always: will this progress? Because MGUS itself, by definition, causes no organ damage and requires no treatment — only surveillance.

Formal Diagnostic Definition (IMWG Criteria)

The formal definition of having MGUS is: ^[1]^[3]

Presence of paraprotein of less than 30 g/L (< 3 g/dL) — AND
Bone marrow plasma cells of < 10%, without
Evidence of B-cell lymphoproliferative disorder — AND
Absence of organ damage (i.e., no CRAB features: hyperCalcaemia, Renal insufficiency, Anaemia, Bone lesions; and no amyloidosis-related organ damage)

"Presence of paraprotein of less than 30g/L AND bone marrow plasma cells of less than 10% without any evidence of B cell lymphoproliferative disorder AND absence of organ damage" ^[1]

MGUS vs Smouldering Myeloma vs Active MM

These three exist on a continuum / spectrum. The key differentiators:

Feature	MGUS	Smouldering MM (SMM)	Active MM
M-protein	< 3 g/dL	≥ 3 g/dL and/or	Any level
BM plasma cells	< 10%	10–60%	≥ 10% (or biopsy-proven plasmacytoma)
End-organ damage (CRAB) or myeloma-defining events (MDEs)	Absent	Absent	Present
Treatment required?	No (monitor)	No (monitor; some high-risk may enter trials)	Yes

2. Epidemiology

MGUS is very common — approximately 5% of the population above 50 years of age ^[1]^[3]

More granular prevalence data ^[2]:

Found in 1–2% of all adults
Prevalence 3.2% in ≥ 50 years
5.3% in ≥ 70 years
7.5% in ≥ 85 years

This makes MGUS far more common than multiple myeloma itself. The vast majority of MGUS patients will never develop myeloma — but because the denominator is so large, MGUS remains the obligate precursor state for virtually all cases of MM.

Age: prevalence increases with age (as above) — median age at diagnosis is 65–70 years ^[2]
Sex: M > F (4.0% vs 2.7% in ≥ 50 years) ^[2]
Ethnicity: African Americans have approximately 2–3× higher prevalence than Caucasians; Asian populations (including Hong Kong Chinese) have somewhat lower rates than Caucasians, though data are limited. The condition is still common in HK's ageing population.
Family: 2.8× increased prevalence in first-degree relatives of MGUS patients ^[2]

HK has a rapidly ageing population → the absolute number of MGUS cases detected incidentally is increasing
MGUS is a common incidental finding when investigating elevated ESR, abnormal globulin levels, or unexplained proteinuria in elderly patients presenting to medical clinics
Myeloma (and by extension, monoclonal gammopathy) is listed as a cause of CKD in HK clinical practice ^[4]

3. Anatomy and Function: The Plasma Cell and Immunoglobulin System

To understand MGUS, you need to understand where plasma cells come from and what immunoglobulins are.

Plasma cells are terminally differentiated B-lymphocytes whose sole function is to secrete large quantities of immunoglobulin (antibody)
Each plasma cell produces immunoglobulin of a single specificity — i.e., one heavy chain class (IgG, IgA, IgM, IgD, IgE) and one light chain type (kappa κ or lambda λ)
Normally, the immune system is polyclonal: thousands of different plasma cell clones each producing different antibodies → the gamma-globulin band on SPEP is a broad smear

An immunoglobulin molecule consists of:

2 heavy chains (determining the class: γ = IgG, α = IgA, μ = IgM, δ = IgD, ε = IgE)
2 light chains (either κ or λ)
Held together by disulfide bonds

In MGUS, a single clone expands and produces a monoclonal immunoglobulin — this appears as a sharp, discrete spike (M-spike) on serum protein electrophoresis, rather than the normal broad polyclonal band.

Plasma cells produce light chains in slight excess of heavy chains
These excess light chains circulate as free light chains (FLC) and are filtered by the kidneys (MW ~22 kDa for monomers, ~44 kDa for dimers)
When FLC are present in urine, they are called Bence Jones protein
The normal serum free κ:λ ratio is approximately 0.26–1.65; an abnormal ratio (< 0.26 or > 1.65) suggests monoclonal origin ^[5]

4. Aetiology and Risk Factors

The exact cause is unknown, but the prevailing understanding is:

Somatic mutations accumulate in a post-germinal-centre B-cell or long-lived plasma cell over a lifetime, giving it a survival and/or proliferative advantage
The abnormal clone expands within the bone marrow niche
At the MGUS stage, the clone is small, proliferating slowly, and does not cause tissue damage
Additional "hits" (further mutations, microenvironmental changes) are required for progression to SMM or MM

Risk Factor	Mechanism / Explanation
Age	Accumulation of somatic mutations over time; declining immune surveillance
Male sex	Unclear; possibly hormonal or occupational exposures
African ancestry	Genetic predisposition (higher prevalence even after adjusting for socioeconomic factors)
Family history	2.8× in first-degree relatives — suggests heritable genetic susceptibility ^[2]
Immunosuppression	HIV, post-transplant immunosuppression → reduced immune surveillance of clonal expansions
Chronic antigenic stimulation	Autoimmune diseases (e.g., RA, SLE), chronic infections → persistent B-cell activation may predispose
Pesticide / herbicide exposure	Epidemiological association (agricultural workers)
Obesity	Adipokine-mediated chronic inflammation may support clonal expansion
Radiation exposure	Historical data from atomic bomb survivors

The risk of progression from MGUS to myeloma is ~1% per year ^[1]^[3]

Risk factors for progression include: ^[1]^[3]

Risk Factor	Explanation
Size of paraprotein	Small = lower chance of progression; larger M-spike (approaching 3 g/dL) = higher risk
Type of paraprotein	Non-IgG types (IgA, IgM) carry higher risk than IgG
Light chain ratio (serum FLC ratio)	Abnormal κ:λ ratio indicates a more established clone
Rate of rise in paraprotein	An evolving (rising) M-protein suggests more aggressive biology
Bone marrow morphology	Higher percentage of plasma cells, abnormal immunophenotype

"Risk of progression to myeloma: Size of paraprotein, Type of paraprotein, Light chain ratio, Rate of rise in paraprotein, Bone marrow morphology" ^[1]

The Mayo Clinic risk stratification model (2005, updated) uses three factors to stratify MGUS risk:

M-protein ≥ 1.5 g/dL
Non-IgG isotype
Abnormal serum FLC ratio

Risk Group	Number of Factors	20-year Progression Risk
Low	0	~5%
Low-intermediate	1	~21%
High-intermediate	2	~37%
High	3	~58%

5. Pathophysiology

In MGUS, a clone of plasma cells (or lymphoplasmacytic cells, in IgM MGUS) has acquired mutations that allow it to:

Self-renew more effectively than normal plasma cells
Resist apoptosis (e.g., via overexpression of BCL-2 family members)
Interact with the bone marrow microenvironment (stromal cells, cytokines like IL-6)

However, the clone is still small (< 10% of BM cellularity) and has not acquired the additional genetic "hits" needed to cause organ damage.

Even at the MGUS stage, clonal plasma cells harbour cytogenetic abnormalities:

Trisomies (hyperdiploidy) — odd-numbered chromosomes
IgH translocations: t(11;14), t(4;14), t(14;16) — these are the same translocations seen in MM, just present earlier
The accumulation of additional mutations (e.g., RAS mutations, MYC translocations, del(17p) with TP53 loss) is what drives progression from MGUS → SMM → MM

At the MGUS stage:

The tumour burden is too low to cause significant bone destruction (osteoclast activation requires a critical mass of myeloma cells secreting RANKL, DKK1, MIP-1α)
The amount of monoclonal light chain produced is insufficient to cause cast nephropathy (myeloma kidney) in most cases
The bone marrow is not sufficiently infiltrated to suppress normal haematopoiesis → no anaemia from marrow failure
Hypercalcaemia does not occur because osteolysis is minimal

Although MGUS is defined by the absence of end-organ damage, the circulating M-protein can still cause:

Laboratory artifacts ^[2]:
- Spuriously low HDL-C level
- High bilirubin level
- Altered inorganic phosphate level
- Apparent high calcium (paraproteins bind calcium, elevating total but not ionised calcium) ^[6]
Elevated ESR: Monoclonal immunoglobulins cause rouleaux formation → markedly elevated ESR (often > 100 mm/hr) even without infection or inflammation
Reversed A:G ratio: ↑ globulin fraction (from the M-protein) with normal or slightly low albumin → reversed albumin-to-globulin ratio ^[2]
Immunoparesis: Even in MGUS, the polyclonal (normal) immunoglobulins may be suppressed — this is because the clonal plasma cells crowd out normal plasma cells and/or immunoregulatory mechanisms suppress them. This is more prominent in higher-risk MGUS.

Factitious Hypercalcaemia in MGUS

Paraproteinaemia with ↑IgM (or other isotypes) can cause factitious ↑Ca due to direct interference ^[6]. The M-protein binds calcium in vitro, raising the total calcium while the ionised calcium remains normal. Always check ionised calcium in patients with paraproteinaemia and apparent hypercalcaemia before assuming true hypercalcaemia! If the ionised calcium is normal, there is no real hypercalcaemia — it is a lab artifact.

6. Classification of MGUS

MGUS is not a single entity — it is classified into subtypes based on the immunoglobulin isotype of the M-protein, which determines the cell of origin and the diseases it may progress to.

Accounts for the majority of MGUS cases
M-protein is IgG (most common, ~69%) or IgA (~11%) ^[2]
Cell of origin: post-germinal centre clonal plasma cell residing in bone marrow
Progression risk: ~0.8% per year ^[2]
Progresses to: multiple myeloma, solitary plasmacytoma, AL amyloidosis ^[2]

M-protein is IgM (~17%) ^[2]
Cell of origin: clonal lymphoplasmacytic cell (a cell intermediate between a B-lymphocyte and a plasma cell)
Progression risk: ~2% per year in the first 10 years, then ~1% per year ^[2]
Progresses to: Waldenström macroglobulinaemia (WM), AL amyloidosis, NHL, CLL ^[2]
IgM MGUS is biologically more closely related to lymphoma than to myeloma

No intact monoclonal immunoglobulin detectable on SPEP
Only an abnormal serum FLC ratio with elevated monoclonal free light chains
Progression risk: ~0.3% per year ^[2]
Progresses to: idiopathic Bence Jones proteinuria (i.e., light-chain SMM), light-chain myeloma, AL amyloidosis

~3% of cases ^[2]
Two distinct M-proteins (either two different heavy chains, or same heavy chain with different light chains)
Managed similarly; each clone assessed independently

Subtype	Isotype	Prevalence	Cell of Origin	Annual Progression Risk	Progresses to
Non-IgM MGUS	IgG (69%), IgA (11%)	Most common	Plasma cell	0.8%/year	MM, plasmacytoma, AL amyloidosis
IgM MGUS	IgM (17%)	Second most common	Lymphoplasmacytic cell	2%/year (first 10y) → 1%/year	WM, NHL, CLL, AL amyloidosis
LC-MGUS	FLC only	Less common	Plasma cell	0.3%/year	LC-MM, AL amyloidosis
Biclonal	Two M-proteins	~3%	Variable	Variable	Depends on constituent clones

MGUS sits within a broader spectrum of plasma cell dyscrasias: ^[5]

"Stage 1: MGUS → Stage 2: Smouldering myeloma → Stage 3: Myeloma (multiple myeloma). Myeloma is a spectrum/timeline, and multiple myeloma is considered to be the 'end-of-the-spectrum' manifestation of plasma cell dyscrasia." ^[3]

"Some patients can convert from MGUS back to normal" ^[3] — meaning the clone can occasionally die out spontaneously, though this is uncommon.

What Determines Progression?

The "multi-hit" model of myelomagenesis:

Initiating events (present even in MGUS): IgH translocations or hyperdiploidy
Early progression events (MGUS → SMM): RAS mutations, NF-κB pathway activation, epigenetic changes
Late progression events (SMM → MM): MYC translocations, del(17p)/TP53 loss, 1q gain, bone marrow microenvironment remodelling (angiogenesis, osteoclast activation, immune evasion)

8. Clinical Features

By definition, MGUS is asymptomatic ^[2]. Patients should have no symptoms attributable to the monoclonal proliferation.

If a patient has symptoms, you must consider whether they have progressed beyond MGUS (to SMM, MM, WM, or amyloidosis) or whether the symptoms are from a separate condition.

However, there are some nuanced clinical scenarios:

Finding	Explanation
Asymptomatic	The hallmark. MGUS is almost always an incidental finding during workup for another condition
Peripheral neuropathy	~5% of MGUS patients develop a distal sensorimotor polyneuropathy, most commonly associated with IgM MGUS (anti-MAG antibody neuropathy). This is technically "MGUS with clinical significance" but by convention still called MGUS unless another diagnosis is made
Increased infection susceptibility	Due to immunoparesis (suppression of normal polyclonal immunoglobulins). Subtle but real

"Only multiple myeloma patients will be symptomatic with organ involvement → requires treatment. Other forms do not require treatment → require monitoring" ^[3]

Physical examination is typically normal in MGUS.

If any of the following signs are present, you should be concerned about progression or an alternative diagnosis:

Sign	What it suggests	Pathophysiological basis
Pallor	Anaemia → possible progression to MM (marrow infiltration) or AL amyloidosis	Clonal plasma cells replacing normal haematopoietic tissue
Bone tenderness	Lytic bone disease → active MM	Osteoclast activation by myeloma cell-derived RANKL, DKK1, MIP-1α
Hepatosplenomegaly	Extramedullary disease (rare in MGUS); consider WM, lymphoma, amyloidosis	Infiltration by malignant cells or amyloid deposition
Macroglossia, periorbital purpura, carpal tunnel	AL amyloidosis	Light chain amyloid fibrils depositing in soft tissues
Peripheral neuropathy signs	IgM-related anti-MAG neuropathy; or AL amyloid neuropathy	Autoantibody against myelin-associated glycoprotein; or amyloid deposition in nerves
Skin changes	Rarely, MGUS-associated conditions (e.g., scleromyxoedema, pyoderma gangrenosum, xanthoma)	Paraprotein deposition in skin
Rouleaux formation on PBS	Not a bedside sign but a laboratory sign — RBCs stack like coins	M-protein increases serum viscosity and bridges RBCs → rouleaux. Non-specific, indicates ↑ protein level ^[2]

The Crucial Clinical Question

When you find an M-protein, the most important question is: "Is this just MGUS, or is there an underlying disease?" You must actively exclude:

Multiple myeloma (CRAB criteria + myeloma-defining events)
AL amyloidosis — "AL amyloidosis is a DDx if patient has suggestive symptoms" ^[1]^[3]
Waldenström macroglobulinaemia (if IgM)
Lymphoma / CLL (if IgM)
Light-chain deposition disease

MGUS is almost always found incidentally during investigation of:

Elevated ESR (very common reason for discovery — the M-protein causes rouleaux → markedly ↑ ESR)
Abnormal total protein / reversed A:G ratio on routine bloods
Unexplained proteinuria (light chains in urine)
Workup for anaemia, bone pain, or renal dysfunction (where MM was suspected but criteria not met)
Unexplained peripheral neuropathy
Hypercalcaemia workup (where factitious hypercalcaemia due to protein binding is identified)

Although MGUS is defined as "undetermined significance," emerging evidence shows that MGUS patients have:

↑ Risk of osteoporosis and fractures — even without lytic lesions; possibly due to low-level osteoclast activation or cytokine effects
↑ Risk of venous thromboembolism — mechanism unclear; possibly related to paraprotein-induced hypercoagulability
↑ Risk of infections — due to immunoparesis
Slightly decreased lifespan: 8.1 years median survival vs 12.4 years in matched controls ^[2], mainly because of the median age at diagnosis (65–70 years) and the 25–30% lifetime risk of progression
Associations with autoimmune diseases and peripheral neuropathy (especially IgM MGUS → anti-MAG neuropathy)
Renal disease: Monoclonal gammopathy of renal significance (MGRS) is a recently recognised entity where the M-protein causes renal damage (e.g., light chain deposition disease, membranoproliferative GN, C3 glomerulopathy) despite not meeting criteria for MM. This is a paradigm shift — the "undetermined significance" becomes renal significance.

MGRS — Monoclonal Gammopathy of Renal Significance

MGRS is a crucial modern concept. These patients have a small clone (meeting MGUS or SMM criteria by marrow involvement) but the monoclonal protein is directly causing kidney damage. Unlike MGUS, these patients require treatment of the clone to halt renal progression, even though they don't have "myeloma." Think of it as: the clone is small but the protein is toxic to the kidney. Key renal lesions include: proliferative GN with monoclonal Ig deposits, C3 glomerulopathy, immunotactoid glomerulopathy, light chain proximal tubulopathy (Fanconi syndrome), and fibrillary GN.

When an M-protein is detected, the following baseline investigations are needed to confirm MGUS and exclude a more advanced disease:

Investigation	Purpose
Serum protein electrophoresis (SPEP) + immunofixation	Detect and quantify M-protein; identify isotype (IgG, IgA, IgM) and light chain type (κ or λ)
Serum free light chains (sFLC) + κ:λ ratio	Detect light-chain-only disease; abnormal ratio suggests monoclonal origin
24-hour urine for Bence Jones protein	Detect monoclonal FLC in urine
CBC / PBS	Exclude cytopenias (anaemia, thrombocytopenia); look for rouleaux
Renal function (creatinine, eGFR)	Exclude renal impairment
Calcium (ionised preferred)	Exclude hypercalcaemia
Serum albumin	Prognostic; low albumin may suggest amyloidosis or more advanced disease
LDH, β2-microglobulin	Prognostic markers (elevated in more advanced disease)
Quantitative immunoglobulins	Assess for immunoparesis (suppression of uninvolved Ig classes)
Bone marrow biopsy	Confirm < 10% clonal plasma cells; cytogenetics/FISH
Skeletal survey / low-dose whole-body CT	Exclude lytic bone lesions

High Yield Summary

MGUS is the most common plasma cell dyscrasia — ~5% of people > 50 years; M > F; prevalence ↑ with age
Definition: M-protein < 3 g/dL, BM plasma cells < 10%, no B-cell lymphoproliferative disorder, no end-organ damage (CRAB)
Three main subtypes: Non-IgM MGUS (most common, IgG > IgA), IgM MGUS (risk of WM/lymphoma), LC-MGUS
Progression risk: Non-IgM ~0.8%/year, IgM ~2%/year, LC ~0.3%/year
Risk factors for progression: Size of M-protein, type (non-IgG worse), abnormal FLC ratio, rate of rise, BM morphology
By definition asymptomatic — always an incidental finding; any CRAB symptom = exclude myeloma
Most important DDx to exclude: AL amyloidosis (especially if suggestive symptoms), MM, WM
Lab artifacts: Elevated ESR, reversed A:G ratio, factitious hypercalcaemia (check ionised Ca), interference with HDL-C, phosphate, bilirubin assays
Management: Monitoring only — no treatment; regular follow-up to detect progression
MGRS is a newer concept where the small clone causes direct renal damage → requires treatment despite not meeting MM criteria

Active Recall - MGUS

Differential Diagnosis of MGUS

The differential diagnosis of MGUS operates on two distinct clinical axes. You need to think about both simultaneously:

Axis 1 — "I've found an M-protein. What could be causing it?" → i.e., what is the differential diagnosis of a monoclonal gammopathy in general? MGUS is only one possibility.
Axis 2 — "The patient has MGUS. What might it progress to or mimic?" → i.e., what conditions must I actively exclude before I can safely label someone as "MGUS"?

These two axes overlap substantially, but framing them separately helps you think systematically.

When you detect an M-protein on serum protein electrophoresis (SPEP), the differential is the entire spectrum of plasma cell dyscrasias and lymphoproliferative disorders plus some reactive/benign causes.

The spectrum of diseases for monoclonal gammopathy includes: ^[7]

Complete Differential of Monoclonal Gammopathy

Category	Condition	Key Distinguishing Features
Plasma cell neoplasms	MGUS	M-protein < 3 g/dL, BM plasma cells < 10%, no end-organ damage ^[1]^[3]
	Smouldering MM (SMM)	M-protein ≥ 3 g/dL and/or BM plasma cells 10–60%, but no CRAB/MDE; 10%/year progression in first 5 years ^[3]
	Active Multiple Myeloma	BM plasma cells ≥ 10% plus CRAB features or myeloma-defining events (see below)
	Solitary plasmacytoma	Single bone or soft-tissue mass of clonal plasma cells; no systemic disease
	Plasma cell leukaemia	Circulating plasma cells > 2 × 10⁹/L or > 20% of WBC differential; aggressive
Lymphoproliferative diseases	Waldenström macroglobulinaemia (WM)	IgM paraproteinaemia + BM shows lymphoplasmacytoid cells ^[5]; hyperviscosity symptoms
	CLL	Clonal mature B-lymphocytes; small M-protein in ~5% of CLL cases
	Indolent B-cell lymphoma (e.g., marginal zone, follicular)	May secrete small amounts of M-protein
Immunoglobulin deposition diseases	AL amyloidosis	Organ deposition of amyloid proteins consisting of monoclonal light chains ^[5]; macroglossia, nephrotic syndrome, cardiomyopathy, neuropathy
	Light chain deposition disease (LCDD)	Organ deposition of light chains that do not form amyloid fibrils ^[5]; often renal (nodular glomerulosclerosis)
	Heavy chain deposition disease	Rare; renal and systemic involvement
Other	POEMS syndrome	Polyneuropathy, Organomegaly, Endocrinopathy, M-protein (usually λ light chain), Skin changes ^[5]
	Heavy chain diseases (α, γ, μ)	Rare; secrete truncated heavy chains without light chains
	Monoclonal gammopathy of renal significance (MGRS)	Clone meets MGUS/SMM criteria by size, but M-protein causes direct renal damage
Reactive / transient	Transient monoclonal gammopathy	Post-infection, post-transplant immune reconstitution; usually disappears spontaneously

"Spectrum of diseases for monoclonal gammopathy: Plasma cell dyscrasia (MGUS → SMM → MM → Extramedullary MM / Plasma cell leukaemia; Plasmacytoma); Lymphoproliferative disease (CLL, Indolent B-cell lymphoma, Waldenström macroglobulinaemia); Amyloid light chain amyloidosis (AL amyloidosis / Primary amyloidosis)" ^[7]

High Yield — GC Lecture Slide

"AL amyloidosis is a DDx if patient has suggestive symptoms" ^[1]. This is the single most important differential to exclude when you diagnose MGUS. Even a small clone can produce enough light chains to cause fatal amyloid deposition in the heart, kidneys, or nerves. If the patient has any suggestive symptoms (unexplained heart failure with preserved EF, nephrotic-range proteinuria, peripheral/autonomic neuropathy, macroglossia, periorbital purpura), you must pursue tissue biopsy with Congo red staining.

Axis 2: Conditions to Actively Exclude Before Labelling "MGUS"

The label "MGUS" is essentially a diagnosis of exclusion. You are saying: "I have found a monoclonal protein, but I have excluded every condition that could explain it." The key conditions you must rule out, and why:

Why? Because MM requires immediate treatment, while MGUS requires only monitoring. The distinction is entirely based on the presence or absence of CRAB criteria and myeloma-defining events (MDEs).

"Only multiple myeloma patients will be symptomatic with organ involvement → requires treatment. Other forms do not require treatment → require monitoring." ^[3]

CRAB criteria (end-organ damage):

C = Calcium elevation (> 0.25 mmol/L above upper limit of normal, or > 2.75 mmol/L)
R = Renal insufficiency (creatinine > 177 μmol/L or eGFR < 40)
A = Anaemia (Hb < 100 g/L or > 20 g/L below lower limit of normal)
B = Bone lesions (lytic lesions on skeletal survey, CT, or PET-CT)

Myeloma-defining events (MDEs) (IMWG 2014 — even without CRAB, these warrant treatment):

BM clonal plasma cells ≥ 60%
Serum FLC ratio ≥ 100 (involved:uninvolved)
1 focal lesion on MRI (≥ 5 mm each)

The haematology lecture case beautifully illustrates a presentation that is not MGUS but active MM: a 65-year-old with pathological fracture, pallor, dehydration, Hb 9.3, Ca 3.3, osteolytic lesions, IgG 6300 with suppressed IgA and IgM, and SPE/immunofixation confirming monoclonal IgG ^[8] — this patient has CRAB features (hypercalcaemia, anaemia, bone lesions) and therefore has active MM, not MGUS.

Why? SMM has a much higher progression risk than MGUS (10%/year in the first 5 years ^[3]) and requires closer monitoring (some high-risk SMM patients may even be considered for early intervention in clinical trials).

Distinguished from MGUS by:

M-protein ≥ 3 g/dL and/or BM plasma cells 10–60%
But still no CRAB/MDE → hence "smouldering" (not yet active)

"Stage 2: Smouldering myeloma — Patient has the distinct feature of abnormal proliferation of clonal plasma cells BUT is asymptomatic, and does not present with any signs of end-organ damage (CRAB)" ^[3]

"AL amyloidosis is a DDx if patient has suggestive symptoms" ^[1]

Why is this so important? Because:

AL amyloidosis can occur with a very small clone — the BM plasma cells may be < 10% and the M-protein < 3 g/dL (i.e., meeting MGUS criteria by tumour burden)
But the light chains are directly toxic — they misfold into amyloid fibrils and deposit in organs
Untreated cardiac AL amyloidosis has a median survival of ~6 months
You can miss it if you only look at the clone size and don't assess for organ deposition

Red flags for AL amyloidosis in a patient labelled "MGUS":

Unexplained heart failure (especially HFpEF with thick walls but low voltages on ECG — "Small complex / Low QRS voltages on ECG, with a very thickened LV wall → CLASSICAL FOR AMYLOIDOSIS" ^[9])
Nephrotic-range proteinuria ("Primary amyloidosis and light chain deposition disease are associated with a monoclonal gammopathy" ^[10])
Peripheral/autonomic neuropathy (postural hypotension, early satiety)
Macroglossia, periorbital purpura, easy bruising (factor X deficiency)
Carpal tunnel syndrome (bilateral)

Diagnosis requires tissue biopsy → Congo red stain → apple-green birefringence under polarised light. Abdominal fat pad aspirate is the least invasive screening site (~80% sensitivity).

Only relevant for IgM MGUS. WM is defined by:

IgM paraproteinaemia + BM infiltration by lymphoplasmacytoid cells ^[5]
Symptoms: hyperviscosity (blurred vision, headaches, mucosal bleeding), lymphadenopathy, hepatosplenomegaly, cytopenias
95% harbour the MYD88 L265P mutation (useful diagnostically)

IgM MGUS has a 2%/year risk of progression in the first 10 years, then ~1%/year → can progress to WM, AL amyloidosis, NHL, CLL ^[2]

Organ deposition of light chains that do not form amyloid fibrils ^[5]
Unlike AL amyloidosis, deposits are granular, Congo red negative
Renal presentation: nephrotic syndrome + renal insufficiency; biopsy shows nodular glomerulosclerosis (can mimic diabetic nephropathy histologically)
"Differential diagnosis includes: Light and heavy chain deposition disease — complication of monoclonal gammopathy" ^[11]

The clone is small (meeting MGUS criteria by size), but the monoclonal protein causes direct renal pathology
Renal lesions include: proliferative GN with monoclonal Ig deposits, C3 glomerulopathy, immunotactoid GN, light chain proximal tubulopathy (acquired Fanconi syndrome), fibrillary GN, type I cryoglobulinaemic GN
Other renal diseases associated with monoclonal light chains: Amyloidosis (AL type), Light chain deposition disease, Light chain proximal tubulopathy, Type I cryoglobulinaemic glomerulonephritis ^[12]
Clinically important because treatment of the clone is needed to prevent progressive renal damage, unlike true MGUS

Low-grade B-cell lymphomas (e.g., marginal zone lymphoma, follicular lymphoma) and CLL may produce small amounts of M-protein
Distinguished by lymphadenopathy, splenomegaly, abnormal lymphocyte counts/morphology, and tissue biopsy

POEMS syndrome ^[5]: Polyneuropathy, Organomegaly, Endocrinopathy, M-protein (usually small, λ light chain), Skin changes
Rare but important; the M-protein is usually small (often would qualify as "MGUS" by level alone), but the clinical syndrome is clearly pathological
Driven by overproduction of VEGF by the clonal plasma cells

Transient M-proteins can appear after:
- Viral infections (EBV, CMV, hepatitis)
- Immune reconstitution post-chemotherapy or post-transplant
- Autoimmune conditions
Usually small (< 1 g/dL) and disappear on repeat testing after weeks to months
Important to repeat SPEP in 2–3 months to confirm persistence before labelling as MGUS

The following table categorises premalignancy and malignancy by monoclonal gammopathy type: ^[7]

Type of Monoclonal Gammopathy	Low-Risk Premalignancy (1–2%/year)	High-Risk Premalignancy (10%/year)	Malignancy
IgG and IgA	Non-IgM MGUS	Smouldering MM (SMM)	MM
IgM	IgM MGUS	Smouldering WM (SWM)	WM; IgM myeloma (rare)
Light chain	Light chain MGUS	Idiopathic Bence Jones proteinuria	Light chain MM

When you encounter an M-protein, think through the following systematic checklist to ensure you are not missing a more serious diagnosis:

Question to Ask	What You're Excluding	How to Answer It
Is the M-protein ≥ 3 g/dL?	SMM or MM	Quantify on SPEP
Are BM plasma cells ≥ 10%?	SMM or MM	Bone marrow biopsy
Is there hypercalcaemia?	MM (CRAB - C)	Serum calcium (ionised preferred in paraproteinaemia)
Is there renal insufficiency?	MM (CRAB - R), MGRS, cast nephropathy, AL amyloidosis	RFT, urine studies, ± renal biopsy
Is there anaemia?	MM (CRAB - A)	CBC
Are there lytic bone lesions?	MM (CRAB - B)	Low-dose whole-body CT or skeletal survey
Is there nephrotic-range proteinuria?	AL amyloidosis, LCDD	24h urine protein, UPCR
Is there unexplained cardiomyopathy?	Cardiac AL amyloidosis, TTR amyloidosis	Echo, ECG, cardiac MRI, ± endomyocardial biopsy
Is there peripheral neuropathy?	AL amyloidosis, POEMS, IgM anti-MAG neuropathy	Nerve conduction studies, anti-MAG antibodies
Is there organomegaly / skin changes / endocrinopathy?	POEMS	Clinical examination, VEGF levels
Is there lymphadenopathy / abnormal lymphocyte count?	Lymphoma, CLL, WM	CBC, CT, ± lymph node biopsy
Is the M-protein IgM?	WM, lymphoma	Isotype on immunofixation

Common Exam Pitfall

A classic exam trap: a patient has a small M-protein, BM plasma cells < 10%, normal CBC, normal calcium, normal creatinine — but has nephrotic-range proteinuria and renal impairment. Students label this as "MGUS" because the clone is small. This is wrong. The correct diagnosis is either AL amyloidosis, LCDD, or MGRS — all require treatment. MGUS is defined by the absence of organ damage attributable to the clone. If the monoclonal protein is damaging an organ, it is not "undetermined significance" — it has determined significance.

An interesting and sometimes-tested laboratory finding:

"Altered anion gap can be seen in paraproteinemia — reduced in IgG gammopathy, increased in IgA gammopathy" ^[13]

Why? The anion gap = Na⁺ − (Cl⁻ + HCO₃⁻). Immunoglobulins are cationic at physiological pH (they carry positive charge). When IgG (the most positively charged Ig at pH 7.4) is present in excess, it acts as an unmeasured cation → the anion gap formula shows a reduced anion gap. IgA is less positively charged and may behave as an unmeasured anion in some assays → increased anion gap. This is a clue on routine bloods that paraproteinaemia may be present.

High Yield Summary — Differential Diagnosis of MGUS

MGUS is a diagnosis of exclusion — you must systematically rule out MM, SMM, AL amyloidosis, WM, LCDD, POEMS, lymphoma/CLL, and MGRS before labelling a monoclonal gammopathy as "undetermined significance."
AL amyloidosis is the most important DDx if the patient has suggestive symptoms ^[1] — even with a small clone, light chains can cause fatal organ damage.
The distinction between MGUS, SMM, and MM is based on three parameters: M-protein level, BM plasma cell percentage, and presence of CRAB/MDE.
IgM MGUS is a distinct entity — the differential includes WM, NHL, and CLL (lymphoproliferative rather than plasma cell lineage).
The monoclonal gammopathy DDx table by isotype ^[7]: Non-IgM MGUS → SMM → MM; IgM MGUS → Smouldering WM → WM; LC-MGUS → Idiopathic Bence Jones proteinuria → LC-MM.
If a small clone causes organ damage (renal, cardiac, neurological), it is not MGUS — consider MGRS, AL amyloidosis, or LCDD.
An altered anion gap (reduced in IgG, increased in IgA gammopathy) can be a laboratory clue to underlying paraproteinaemia.

Active Recall - Differential Diagnosis of MGUS

References

^[1] Lecture slides: GC 030. An old man with bone pain and anaemia.pdf (MGUS slide) ^[2] Senior notes: Ryan Ho Haemtology.pdf (Section 3.6.2 Monoclonal Gammopathy of Undetermined Significance) ^[3] Senior notes: Block A - An old man with bone pain and anaemia_ multiple myeloma; monoclonal gammopathy.pdf (Development of myeloma / MGUS section) ^[4] Senior notes: Block A - Chronic Kidney Disease and its Complications.pdf (Causes of CKD) ^[5] Senior notes: Maksim Medicine Notes.pdf (Spectrum of plasma cell dyscrasias) ^[7] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (Differential diagnosis — Spectrum of diseases for monoclonal gammopathy) ^[8] Lecture slides: Haematology Introduction to Haematological investigations (CBP, Clotting).pdf (Case 1) ^[9] Senior notes: Block A - Inherited Cardiac conditions.pdf (Amyloidosis workup in DCM) ^[10] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (Serum and urine immunofixation for amyloidosis/LCDD) ^[11] Senior notes: Block A – Nephrology Data Interpretation.pdf (Light and heavy chain deposition disease as DDx) ^[12] Senior notes: Block A - Nephrotology Teaching Clinic RTD.pdf (Renal diseases associated with monoclonal light chains) ^[13] Senior notes: Block A - Electrolyte and Acid-Base Disorders.pdf (Altered anion gap in paraproteinaemia)

Diagnostic Criteria, Algorithm, and Investigations for MGUS

MGUS is defined by the International Myeloma Working Group (IMWG) criteria. All four criteria must be met simultaneously. Think of it as a four-lock safe — every lock must click shut before you can confidently label something as MGUS.

"Presence of paraprotein of less than 30g/L AND bone marrow plasma cells of less than 10% without any evidence of B cell lymphoproliferative disorder AND absence of organ damage" ^[1]

Criterion	Threshold	Why This Threshold?
1. Serum M-protein	< 3 g/dL (< 30 g/L)	Higher levels correlate with larger clonal burden → more likely SMM/MM. The 3 g/dL cut-off was derived from population studies showing exponentially ↑ progression risk above this level.
2. Bone marrow clonal plasma cells	< 10%	≥ 10% indicates SMM or MM. Even a small percentage confirms clonality exists, but < 10% is consistent with a clinically indolent clone.
3. No evidence of B-cell lymphoproliferative disorder	Exclude lymphoma, CLL, WM	Because a small M-protein can be the "tip of the iceberg" of an underlying lymphoid malignancy producing the monoclonal Ig.
4. Absence of end-organ damage	No CRAB features, no MDE	This is the critical dividing line between MGUS and active MM. End-organ damage = the clone is causing harm = treatment is needed.

High Yield — GC Lecture Slide

The GC 030 slide explicitly states the definition as a single compound statement. In exams, you will likely be asked to recall all four criteria. A common mistake is forgetting "without any evidence of B cell lymphoproliferative disorder" ^[1] — students often list only three criteria (M-protein, BM %, organ damage) and miss the lymphoproliferative exclusion.

The diagnostic criteria of MGUS vs SMM vs active MM: ^[5]^[3]^[14]

Feature	MGUS	Smouldering MM	Active MM
Serum M-protein	< 3 g/dL (< 30 g/L) ^[1]	≥ 3 g/dL and/or	Any level
BM plasma cells	< 10% ^[1]	10–60%	≥ 10% (or biopsy-proven plasmacytoma) ^[14]
End-organ damage (CRAB)	Absent ^[1]	Absent	Present
Myeloma-defining events (SLiM)	Absent	Absent	Present (if any one is met, = active MM even without CRAB)
Treatment	Monitoring only ^[2]	Monitoring (high-risk may enter trials)	Chemotherapy indicated ^[5]
Progression risk	1%/year ^[3]	10%/year (first 5 years) ^[3]	Already progressed

These are the criteria that exclude MGUS (i.e., if any of these are present and attributable to the plasma cell clone, the patient has active MM, not MGUS):

End-organ damage: CRAB ^[5]

Letter	Feature	Threshold	Pathophysiology
C	Calcium	Adjusted Ca > 2.75 mmol/L (or > 0.25 above ULN)	Osteoclast activation by myeloma cells → bone resorption → Ca²⁺ release
R	Renal insufficiency	Creatinine > 177 μmol/L or CrCl < 40 mL/min	Cast nephropathy (FLC obstruct tubules), hypercalcaemia, amyloid
A	Anaemia	Hb < 100 g/L (or > 20 g/L below LLN)	BM infiltration by plasma cells crowding out erythropoiesis
B	Bone disease	Osteolytic "punched-out" lesions on CT/PET-CT/whole-body MRI	RANKL/DKK1/MIP-1α from myeloma cells activate osteoclasts; ALP usually normal because osteoblastic activity is normal ^[5]

Biomarkers of malignancy: SLiM ^[5]

Letter	Feature	Threshold	Rationale
S	Sixty	Clonal BM plasma cells ≥ 60%	Ultra-high tumour burden → virtually certain progression
Li	Light chain ratio	Involved/uninvolved serum FLC ratio > 100	Very skewed ratio indicates aggressive monoclonal light chain production
M	MRI focal lesions	> 1 focal lesion on MRI (each ≥ 5 mm)	Radiological evidence of marrow involvement even without lytic destruction

Why SLiM Matters

Before 2014, patients needed overt CRAB damage before they could be diagnosed with active MM. The IMWG added SLiM criteria because studies showed that patients meeting any one of these biomarker thresholds had an ~80% risk of progressing to CRAB damage within 2 years if left untreated. So SLiM = "ultra-high-risk SMM" that is effectively relabelled as active MM to mandate early treatment.

The diagnostic workup for MGUS follows a stepwise approach: first detect the M-protein, then characterise it, then systematically exclude more advanced disease.

3. Investigation Modalities — Detailed Interpretation

What it is: Serum proteins are separated by electrical charge on a gel/capillary. Normally, the gamma-globulin region shows a broad, polyclonal band (many different Ig from many different clones). A monoclonal protein appears as a sharp, narrow spike (M-spike) within or near the gamma region.

"SPE: quantification of M protein" ^[5]

How to interpret the four patterns of SPE: ^[15]

Pattern	Description	What It Suggests
Normal Ig pattern, absence of paraprotein	Single albumin peak; low flat gamma band	Normal (but could also be non-secretory myeloma — rare)
Pan-immunoparesis	All bands low/flat, no peaks	Inherited or acquired immunodeficiencies; light chain myeloma; IgD myeloma; non-secretory myeloma
Raised immunoglobulin, absence of paraprotein	Broad elevated gamma band (polyclonal)	Polyclonal hypergammaglobulinaemia — reactive process (chronic infection, autoimmune, liver cirrhosis). Not a plasma cell problem → DO NOT refer to haematology
Presence of paraprotein ± immunoparesis	Sharp M-spike ± suppression of background Ig	Monoclonal gammopathy — requires further workup

In MGUS, the pattern is typically: small M-spike (< 3 g/dL) ± mild immunoparesis of uninvolved immunoglobulins

Common Exam Point

"Raised immunoglobulin, absence of paraprotein on SPE → polyclonal hypergammaglobulinaemia → reactive process → DO NOT refer to haematology" ^[15]. Students sometimes confuse a polyclonal elevation with a monoclonal spike. The key visual clue: polyclonal = broad dome; monoclonal = sharp spike.

What it is: After electrophoresis, specific antisera are overlaid against each heavy chain (IgG, IgA, IgM) and each light chain (κ, λ). The antiserum that "fixes" (precipitates) the M-band tells you exactly what type of monoclonal protein is present.

"Immunofixation: characterize type of M protein, e.g. IgGκ (most common)" ^[5]

Why it matters for MGUS:

Determines the isotype — this feeds into risk stratification (non-IgG type = higher risk of progression)
IgM isotype shifts the differential toward WM/lymphoma rather than MM
"Both SPE and UPE at diagnosis is mandatory: 50% of light chain MM is SPE-negative but UPE-positive" ^[5] — this isn't directly about MGUS, but it reminds you to always do urine studies to catch light-chain-only disease

What it is: A quantitative assay measuring unbound (free) κ and λ light chains in serum, plus their ratio.

Normal κ:λ ratio: 0.26–1.65 ^[5]
An abnormal ratio indicates monoclonal excess of one light chain type
"Serum FLC: more sensitive for monoclonal FLC, κ:λ ratio also suggests monoclonal origin" ^[5]

Why it matters for MGUS:

Diagnosis of LC-MGUS: some patients have no intact M-protein on SPEP but an abnormal FLC ratio — this is light-chain MGUS
Risk stratification: an abnormal FLC ratio is one of the three factors in the Mayo Clinic risk model
Progression to MM: a ratio > 100 is a myeloma-defining event (SLiM criteria) ^[5]
"Light chain ratio approaching 100 = poor prognostic marker" ^[3]

Urine protein electrophoresis (UPE) with immunofixation: detects monoclonal free light chains (Bence Jones protein) in urine
"24h urine: Bence Jones protein (FLC)" ^[5]
In MGUS, Bence Jones protein may be absent or present in small quantities (< 500 mg/24h by convention)
Heavy proteinuria (> 1 g/day of monoclonal light chains) should raise concern for SMM, MM, AL amyloidosis, or cast nephropathy

Why "Bence Jones"? Named after Henry Bence Jones (1848) who described urine proteins that precipitate when heated to 56°C and redissolve at 100°C. These are monoclonal free light chains that are small enough to pass through the glomerular filter.

In MGUS, CBC/PBS are usually normal ± rouleaux formation ^[2]

Finding	Interpretation	Pathophysiology
Normal Hb	Expected in MGUS (no marrow failure)	Clone too small to crowd out erythropoiesis
Rouleaux formation	Non-specific; indicates ↑ protein level ^[2]	M-protein bridges RBC surfaces → stacking like coins; causes falsely ↑ ESR
Anaemia	If present → consider MM, AL amyloidosis, or other cause	BM infiltration, EPO deficiency from renal impairment, or haemodilution
Circulating plasma cells	> 2 × 10⁹/L or > 20% WCC → plasma cell leukaemia ^[16]	Fulminant disease; excludes MGUS

Test	Expected in MGUS	Abnormal Values and What They Suggest
Calcium	Normal	↑ Ca → MM (osteolysis) or factitious (paraprotein binding); always check ionised Ca in paraproteinaemia ^[6]
Creatinine/eGFR	Normal	↑ Cr → cast nephropathy, MGRS, amyloidosis, hypercalcaemia
Albumin	Normal or mildly ↓	↓ Albumin → advanced disease (prognostic in ISS staging), AL amyloidosis
LDH	Normal	↑ LDH → aggressive disease, R-ISS staging
β2-microglobulin	Normal or mildly ↑ with age	Important for prognosis; must be checked at diagnosis as levels change after treatment ^[16]; ↑ in renal impairment or high tumour burden
Quantitative Ig (IgG, IgA, IgM)	Usually normal or mild immunoparesis	Immunoparesis = suppression of uninvolved Ig classes → ↑ infection risk; more pronounced = more concerning
Total protein + A:G ratio	Reversed A:G ratio with ↑ globulin ^[2]	Albumin remains normal but globulin rises due to M-protein → A:G inverts
ESR	Elevated (often markedly) ^[2]	Rouleaux → ↑ sedimentation; can be > 100 mm/hr with even modest M-proteins

Chemical Pathology Pearl — Factitious Hypercalcaemia

"Paraproteinaemia, e.g. MGUS — significantly ↑ total protein with normal albumin → ↑ globulin; apparent high Ca → due to high globulin; Ig may precipitate with PO₄, interfering with measurement" ^[6]. In the exam, if you see ↑ total calcium + ↑ globulin + normal albumin in an elderly patient, think: Is this real hypercalcaemia or a paraprotein artifact? Check ionised calcium.

This is the definitive investigation for confirming MGUS (and excluding MM/SMM).

"BM: by definition < 10% clonal plasma or lymphoplasmacytic cells" ^[2]

Component	What It Shows	Why It's Needed
Aspirate (smear)	Permits cytology, flow cytometry, and genetic studies ^[17]	Count plasma cell %, assess morphology
Trephine biopsy	Permits histological examination (marrow cellularity, architectural details, fibrosis, bone structure) and immunohistochemistry ^[17]	Detect patchy involvement (aspirate may falsely underestimate); IHC for CD138, κ/λ restriction
Morphology	Generally round, eccentric 'clock-face' nucleus with marked perinuclear cytoplasmic clearing ^[16]	Typical plasma cell morphology; atypical/immature morphology suggests more aggressive disease
Immunophenotyping	CD138, κ/λ light chain expression ^[16]	Confirms clonality (light chain restriction = all cells express same LC type)
Cytogenetics/FISH	Detect IgH translocations, hyperdiploidy, del(17p), 1q gain	Risk stratification; high-risk cytogenetics [t(4;14), del(17p)] suggest closer monitoring even in "MGUS"

"Bone marrow morphology" is listed as one of the five risk factors for progression on the GC lecture slide ^[1]. "Ugly looking plasma cells, clinical course worse" ^[3].

Is BM Biopsy Always Needed in Suspected MGUS?

Technically, the IMWG definition requires BM confirmation of < 10% clonal plasma cells. However, in clinical practice, some guidelines allow deferral of BM biopsy in low-risk patients (IgG type, M-protein < 1.5 g/dL, normal FLC ratio, no symptoms). The decision is individualised. In an exam setting, always mention BM biopsy as part of the diagnostic workup.

The purpose is to exclude lytic bone lesions (CRAB — B criterion), which would upgrade the diagnosis from MGUS to active MM.

"Skeletal survey – hypermetabolic lesions with PET/CT and bone scintigraphy" ^[11]

Modality	Details	Findings in MGUS vs MM
Skeletal survey (conventional X-ray)	PA chest, AP/lateral C/T/L-spine, AP/lateral femur/humerus, AP/lateral skull, AP pelvis ^[16]	MGUS: normal. MM: punched-out lytic lesions (60%), diffuse osteopenia, pathological fractures (20%) ^[16]
Whole-body low-dose CT	Now preferred due to ↑ sensitivity ^[16]	More sensitive than plain X-ray for small lytic lesions
Whole-body MRI	Excellent soft-tissue contrast; detects marrow infiltration	> 1 focal lesion ≥ 5 mm = myeloma-defining event (SLiM — M)
PET/CT	Detects hypermetabolic lesions	Usually preferred in QMH ^[16]; functional + anatomical

Why is ALP usually normal in myeloma? Because myeloma activates osteoclasts (bone breakdown) but does not activate osteoblasts (bone formation). ALP is produced by osteoblasts, so it stays normal. This distinguishes myeloma lytic lesions from metastatic carcinoma (which often has ↑ ALP due to mixed lytic-blastic response). ^[5]

If there is any clinical suspicion of organ deposition:

Investigation	Purpose
Abdominal fat pad aspirate	Least invasive screening biopsy for amyloid; Congo red stain → apple-green birefringence under polarised light
Tissue biopsy (renal, endomyocardial, rectal)	Direct demonstration of amyloid deposits in affected organ
Congo red stain → salmon pink colour	Indicative of amyloid deposition ^[18]
Electron microscopy	Non-branching fibrils in the extracellular compartment ^[18]
NT-proBNP, Troponin	Cardiac biomarkers for subclinical cardiac amyloid involvement
Echocardiography + ECG	Small QRS voltages + thickened LV wall = classical for amyloidosis ^[9]
99mTc-PYP scan	For transthyretin (TTR) amyloidosis ^[9] — important to distinguish AL from ATTR

These are not for MGUS itself (which requires no treatment) but are important to know as part of the myeloma workup if the patient progresses:

"Pre-Tx: HBsAg, anti-HBc ± HBV DNA, G6PD" ^[5] — because:

HBV screening: immunomodulatory therapy (e.g., lenalidomide) and steroids can cause HBV reactivation → must screen before starting
G6PD: some chemotherapy agents can cause haemolysis in G6PD-deficient patients

4. Risk Stratification of Confirmed MGUS

Once MGUS is confirmed, the next step is risk stratification to determine follow-up intensity.

Uses three factors:

Factor	Threshold
1. M-protein level	≥ 1.5 g/dL
2. Isotype	Non-IgG (i.e., IgA, IgM)
3. Serum FLC ratio	Abnormal (< 0.26 or > 1.65)

Risk Group	Number of Risk Factors	Absolute Risk of Progression at 20 Years
Low	0	~5%
Low-intermediate	1	~21%
High-intermediate	2	~37%
High	3	~58%

Risk of progression to myeloma depends on: Size of paraprotein, Type of paraprotein, Light chain ratio, Rate of rise in paraprotein, Bone marrow morphology ^[1]

Risk Category	Recommended Follow-Up
Low risk (0 factors)	Repeat SPEP, sFLC, CBC, Ca, creatinine at 6 months, then if stable, every 2–3 years or when symptoms develop
Intermediate/High risk (1–3 factors)	Repeat at 6 months, then annually with SPEP, sFLC, CBC, Ca, creatinine
Any category — new symptoms	Immediate reassessment with full workup (BM biopsy, imaging)

The key variables to monitor at each visit:

M-protein level (is it rising? — "Rate of rise in paraprotein — rapid rise is alarming, require monitoring soon" ^[3])
sFLC ratio (is it becoming more abnormal?)
CBC (new anaemia?)
Calcium (new hypercalcaemia?)
Creatinine (new renal impairment?)
Symptoms: new bone pain, fatigue, weight loss, recurrent infections

Investigation	Key Finding in MGUS	What an Abnormality Means
SPEP	M-spike < 3 g/dL	> 3 g/dL → SMM/MM
Immunofixation	Identifies isotype (IgG κ most common)	IgM → think WM; Non-IgG → ↑ risk
sFLC + ratio	May be normal or mildly abnormal (ratio 0.26–1.65)	Ratio > 100 → MDE (active MM)
24h urine + UPE	Absent or minimal Bence Jones protein	Heavy BJP → SMM/MM/AL amyloidosis
CBC/PBS	Normal ± rouleaux	Anaemia → MM; Circulating plasma cells → PCL
Calcium (ionised)	Normal	↑ → MM (or factitious if total Ca only)
RFT	Normal	↑ Cr → cast nephropathy/MGRS/amyloid
Quantitative Ig	Normal or mild immunoparesis	Severe immunoparesis → closer monitoring
β2-microglobulin	Normal or age-related mild ↑	↑ → staging (ISS) for MM
BM biopsy	< 10% clonal plasma cells	≥ 10% → SMM/MM
Skeletal imaging	Normal	Lytic lesions → MM
Tissue biopsy (if indicated)	No amyloid	Congo red +ve → AL amyloidosis

High Yield Summary — Diagnostic Criteria, Algorithm, and Investigations

MGUS diagnostic criteria (all must be met): M-protein < 3 g/dL; BM plasma cells < 10%; no B-cell lymphoproliferative disorder; no end-organ damage (CRAB/SLiM) ^[1]
CRAB = Calcium ↑, Renal insufficiency, Anaemia, Bone lesions. SLiM = Sixty % BM PC, Light chain ratio > 100, MRI > 1 focal lesion. Any CRAB or SLiM = active MM, not MGUS ^[5]
Investigation trio for monoclonal gammopathy screening: SPEP with immunofixation + serum FLC + 24h urine for BJP ^[5]
SPEP patterns: Normal / Pan-immunoparesis / Polyclonal ↑ (reactive, do NOT refer to haematology) / M-spike ± immunoparesis ^[15]
Normal κ:λ ratio = 0.26–1.65; abnormal suggests monoclonal origin ^[5]
BM biopsy is definitive: confirms < 10% clonal PC, provides morphology, immunophenotyping (CD138, light chain restriction), and cytogenetics for risk stratification
Skeletal imaging (WB low-dose CT preferred) must be normal in MGUS; ALP is usually normal in myeloma because osteoblastic activity is preserved ^[5]
Risk stratification: Mayo Clinic model uses M-protein ≥ 1.5, non-IgG isotype, abnormal FLC ratio → 0–3 risk factors determining surveillance intensity
Always exclude AL amyloidosis if any suggestive symptoms — even a small clone can produce lethal amyloid deposits ^[1]
Factitious hypercalcaemia: paraprotein binds calcium → ↑ total Ca with normal ionised Ca; check ionised Ca ^[6]

Active Recall - Diagnostic Criteria, Algorithm, and Investigations for MGUS

References

^[1] Lecture slides: GC 030. An old man with bone pain and anaemia.pdf (MGUS slide) ^[2] Senior notes: Ryan Ho Haemtology.pdf (Section 3.6.2 Monoclonal Gammopathy of Undetermined Significance) ^[3] Senior notes: Block A - An old man with bone pain and anaemia_ multiple myeloma; monoclonal gammopathy.pdf (Development of myeloma / MGUS section) ^[5] Senior notes: Maksim Medicine Notes.pdf (Multiple myeloma investigations, diagnostic criteria, SLiM CRAB) ^[6] Senior notes: Ryan Ho Chemical Path.pdf (Paraproteinaemia and factitious hypercalcaemia) ^[8] Lecture slides: Haematology Introduction to Haematological investigations (CBP, Clotting).pdf (Case 1) ^[9] Senior notes: Block A - Inherited Cardiac conditions.pdf (Amyloidosis workup in DCM) ^[11] Senior notes: Block A – Nephrology Data Interpretation.pdf (Skeletal survey, monoclonal gammopathy workup) ^[14] Senior notes: Block A - An old man with bone pain and anaemia_ multiple myeloma; monoclonal gammopathy.pdf (MGUS vs SMM vs MM comparison table) ^[15] Senior notes: Block A - Introduction to Haematological investigations (CBP, Clotting).pdf (Interpretation of SPE — 4 patterns) ^[16] Senior notes: Ryan Ho Haemtology.pdf (MM laboratory findings, skeletal imaging, ISS staging) ^[17] Senior notes: Ryan Ho Fundamentals.pdf (Bone marrow examination — aspirate vs trephine) ^[18] Senior notes: Block A - Hematology Data Interpretation.pdf (Congo red stain, electron microscopy for amyloidosis)

Management of MGUS

Before diving into the algorithm, the single most important concept must be crystal clear:

"Only multiple myeloma patients will be symptomatic with organ involvement → requires treatment. Other forms do not require treatment → require monitoring." ^[3]

MGUS management is monitoring only ^[2]. There is no chemotherapy, no immunotherapy, no radiation for MGUS itself. This is not a disease that requires treatment — it is a risk state that requires surveillance. The entire management strategy is about two things:

Confirming the diagnosis is truly MGUS (not something masquerading as MGUS)
Detecting progression early before irreversible organ damage occurs

Why no treatment? Because:

The clone is too small to cause harm
Available therapies carry toxicity (immunosuppression, neuropathy, secondary malignancies)
The annual progression risk is only ~1% — treating all MGUS patients would mean subjecting ~99 people per year to toxic therapy unnecessarily for every 1 who would progress
Some patients can convert from MGUS back to normal ^[3] — the clone can spontaneously regress

3. Detailed Management Components

Risk of progression to myeloma depends on: Size of paraprotein, Type of paraprotein, Light chain ratio, Rate of rise in paraprotein, Bone marrow morphology ^[1]

The Mayo Clinic model is the most widely used clinical tool:

Risk Factors Present	Risk Group	20-year Progression	Suggested Follow-up
0 of 3	Low	~5%	6 months → every 2–3 years
1 of 3	Low-intermediate	~21%	6 months → annually
2 of 3	High-intermediate	~37%	6 months → every 6–12 months
3 of 3	High	~58%	6 months → every 6–12 months

The Spanish PETHEMA model adds BM immunophenotyping (aberrant vs normal plasma cell phenotype) and DNA aneuploidy as additional discriminators, but the Mayo model is more commonly referenced in HK exams.

At each surveillance visit, the following should be assessed:

Test	What You're Looking For	Rationale
SPEP with immunofixation	Rising M-protein level; appearance of new M-protein	"Rate of rise in paraprotein — rapid rise is alarming, require monitoring soon" ^[3]. A rise of ≥ 0.5 g/dL/year or M-protein crossing 3 g/dL suggests transition to SMM.
Serum free light chains + κ:λ ratio	Increasingly abnormal ratio; ratio approaching or exceeding 100	"Light chain ratio approaching 100 = poor prognostic marker" ^[3]. A ratio > 100 = myeloma-defining event → immediate action
CBC	New anaemia (Hb < 100), new cytopenias	Anaemia = CRAB criterion (A). New thrombocytopenia or leukopenia suggests marrow infiltration
Serum calcium (ionised preferred)	New hypercalcaemia	CRAB criterion (C). Remember to always check ionised Ca to avoid being misled by factitious hypercalcaemia from paraprotein binding ^[6]
Serum creatinine / eGFR	New renal impairment	CRAB criterion (R). Decline in eGFR may indicate cast nephropathy, amyloidosis, or LCDD
Clinical assessment	New bone pain, fatigue, weight loss, recurrent infections, neuropathy, features of amyloidosis	Any new symptom warrants expedited full workup

When to Urgently Re-Evaluate

The patient should be educated to return immediately (not wait for scheduled follow-up) if they develop:

New bone pain (especially back, ribs, pelvis)
Unexplained fatigue or pallor
Recurrent or severe infections
Excessive thirst/polyuria (hypercalcaemia)
Foamy urine (proteinuria)
Numbness/tingling in hands/feet (neuropathy → amyloidosis or POEMS)
Swelling of ankles (nephrotic syndrome → amyloidosis)

BM biopsy is not repeated routinely in stable MGUS. It is indicated when:

M-protein rises significantly (e.g., ≥ 25% increase from baseline, or crosses 3 g/dL)
sFLC ratio becomes markedly abnormal
New CRAB features develop
Clinical suspicion of transformation (new symptoms, new cytopenias)

3.4 Addressing Associated Risks in MGUS Patients

Although MGUS doesn't require anti-neoplastic treatment, these patients face real health risks that warrant proactive management:

MGUS patients have a 2–3× increased risk of osteoporotic fracture compared to age-matched controls, even without lytic lesions. The mechanisms include:

Low-level osteoclast activation by clonal plasma cell-derived cytokines (RANKL, DKK1)
Immunoparesis → chronic inflammation → bone loss
Older age (the population most affected by MGUS is already at risk)

Management:

DXA scan for baseline BMD assessment
Vitamin D and calcium supplementation as appropriate
Bisphosphonates are NOT routinely given for MGUS alone (unlike active MM), but may be indicated if the patient has coexisting osteoporosis by standard criteria

MGUS patients have immunoparesis — suppression of uninvolved (normal, polyclonal) immunoglobulins. This translates to a real, measurable increase in infection risk, particularly for encapsulated organisms.

Management:

Annual influenza vaccination
Pneumococcal vaccination (PCV20 or PCV15 + PPSV23 sequential strategy)
COVID-19 vaccination (MGUS patients may have suboptimal antibody responses)
Low threshold for investigating febrile illness — counsel patient and GP

MGUS is associated with a ~2× increased risk of VTE. The mechanism is likely multifactorial:

Paraprotein-mediated activation of coagulation pathways
Acquired activated protein C resistance
Possible anti-phospholipid antibody-like activity of the M-protein

Management:

No routine anticoagulation (the risk is too small to justify)
Patient education on VTE symptoms (leg swelling, sudden breathlessness)
Attention to VTE prophylaxis during hospitalisation or surgery

Even in "true" MGUS, there is a small risk of the monoclonal protein causing subclinical renal damage (the spectrum of MGRS — Monoclonal Gammopathy of Renal Significance). Routine monitoring of creatinine and urinalysis helps catch this early.

If proteinuria develops → check urine protein quantification and refer for nephrology evaluation ± renal biopsy.

4. What Happens If MGUS Progresses?

Although this section focuses on MGUS management (which is surveillance), it is important to understand the framework of what follows if progression occurs, as this is commonly tested.

M-protein rises ≥ 3 g/dL and/or BM plasma cells reach 10–60%
Still no CRAB/SLiM
Management: closer monitoring (every 3–6 months); some centres enrol high-risk SMM patients in clinical trials of early intervention (e.g., lenalidomide-based regimens), but standard of care remains observation outside trials

When any CRAB or SLiM criterion is met, the patient is reclassified as active MM and specific chemotherapy is indicated ^[5]:

"Specific chemotherapy: only indicated in active MM" ^[5]

The MM treatment framework (for context — not treatment of MGUS itself):

Phase	Regimen	Key Agents
Induction	Triple therapy ^[5]	Proteasome inhibitor (e.g., bortezomib, carfilzomib) + Immunomodulatory agent (e.g., lenalidomide, thalidomide, pomalidomide) + Dexamethasone
Transplant assessment	Determine eligibility	Age < 60, no significant comorbidities ^[5]
Transplant eligible	4 cycles triple therapy → high-dose melphalan + autologous HSCT ^[5]	Melphalan = alkylating agent that ablates BM
Transplant ineligible	8–12 cycles of triple therapy ^[5]	Extended induction without transplant
Consolidation + Maintenance	Lenalidomide monotherapy ≥ 2 years ^[5]	Maintains response, delays relapse
Relapsed/Refractory	Anti-CD38 (daratumumab, isatuximab), SLAMF7 (elotuzumab) ^[5]	Monoclonal antibodies targeting myeloma cells
Immunotherapy against BCMA	ADC, BiTE, CAR-T ^[5]	Newest modalities for multiply-relapsed disease

Supportive treatment for active MM: ^[5]

TLS prophylaxis: IV fluid + allopurinol/febuxostat
Hypercalcaemia/Bone disease: local RT for pain, aggressive hydration > 3L/day, bisphosphonates (e.g., pamidronate), denosumab (RANKL inhibitor)
Renal failure: hydration, avoid nephrotoxins (e.g., NSAID), dialysis PRN

Why These Agents Are NOT Used in MGUS

Let's briefly understand why each class of MM drug would be inappropriate for MGUS:

Proteasome inhibitors (bortezomib): "Inhibition of 26S proteasome → prevent proteolysis of ubiquitin-tagged protein → cytotoxic to myeloma cells by affecting multiple signalling cascades" ^[14]. Side effects include peripheral neuropathy, thrombocytopenia, and herpes zoster reactivation. Giving this to a patient with a benign, asymptomatic condition would cause harm without benefit.
Immunomodulatory agents (lenalidomide, thalidomide): Teratogenic, cause cytopenias, increase VTE risk. The risk-benefit ratio is only favourable when the alternative is death or organ destruction from myeloma.
Dexamethasone: Chronic high-dose steroids cause cushingoid features, diabetes, osteoporosis, immunosuppression. Justified only when controlling aggressive disease.
HSCT: Carries 1–2% treatment-related mortality. Only justified when the disease itself threatens life.

The principle: primum non nocere (first, do no harm). MGUS patients live with their condition for years to decades. Exposing them to toxic therapy for a 1%/year progression risk would cause far more harm than good.

"AL amyloidosis is a DDx if patient has suggestive symptoms" ^[1]

If an MGUS patient develops features of AL amyloidosis (cardiac failure, nephrotic syndrome, neuropathy, macroglossia), tissue biopsy confirmation is needed, followed by clone-directed therapy:

Similar agents to myeloma (bortezomib-based regimens, ± daratumumab)
Goal: eradicate or suppress the clone to halt light chain production and amyloid deposition
Supportive: diuretics for fluid overload, pacemaker for conduction disease, ACEi contraindicated (can cause profound hypotension in cardiac amyloid)

If IgM MGUS progresses to symptomatic WM (hyperviscosity, cytopenias, lymphadenopathy):

Treatment: rituximab-based regimens (rituximab + bendamustine, or rituximab + ibrutinib)
Plasmapheresis for acute hyperviscosity syndrome

5. Special Situations in MGUS Management

Important to document MGUS in surgical pre-assessment
Elevated ESR and abnormal globulins should not delay surgery (they are expected findings)
Ensure VTE prophylaxis is adequate (MGUS ↑ VTE risk)
Avoid nephrotoxic agents peri-operatively (NSAIDs, contrast dye — always hydrate well)

IV iodinated contrast is generally safe in MGUS with normal renal function
In patients with Bence Jones proteinuria or borderline renal function → ensure aggressive pre- and post-hydration to prevent contrast-induced nephropathy and cast nephropathy exacerbation

Bisphosphonates are NOT routinely indicated for MGUS (unlike active MM where they are standard)
However, if the patient has coexisting osteoporosis (T-score ≤ −2.5 on DXA), bisphosphonates are given for osteoporosis per standard guidelines
"IV bisphosphonates cannot be used in patients with eGFR less than 35 mL/min → denosumab not excreted through kidneys, can be given to these CKD patients" ^[19] — relevant if the MGUS patient has coexisting CKD

IgM MGUS-associated anti-MAG neuropathy may warrant treatment even though the "MGUS" clone itself is small
Options: rituximab (targets the IgM-producing clone), IVIG, plasma exchange
This is technically treating the consequences of the monoclonal protein, not treating MGUS as a malignancy

As discussed in previous sections, MGRS is MGUS-level clone burden but with direct renal pathology
Treatment of the clone IS indicated in MGRS — because the kidney damage will progress without intervention
Regimens are clone-directed, similar to myeloma induction (bortezomib-based), tailored to the specific renal lesion

An often-overlooked but critically important aspect of MGUS management. Telling a patient they have a "pre-cancer" condition requires careful communication:

Key Message	How to Frame It
"You have an abnormal protein in your blood"	Explain simply: one of your immune cells is making too much of one type of protein
"It is NOT cancer"	Currently no damage to your body; it's a risk state, like having high cholesterol is a risk for heart disease
"It needs monitoring, not treatment"	We follow it with regular blood tests, like we monitor blood pressure
"The risk of it progressing is small"	~1% per year; the vast majority of people with MGUS never develop a problem
"Come back if you have new symptoms"	Bone pain, unusual fatigue, recurrent infections, swelling → tell us immediately

Component	Action	Rationale
Anti-neoplastic therapy	NOT indicated	Risk-benefit ratio unfavourable; clone is benign by definition
Risk stratification	Mayo Clinic model (3 factors)	Determines surveillance intensity
Surveillance bloods	SPEP, sFLC, CBC, Ca, Cr	Detect rising M-protein, new CRAB criteria
Surveillance schedule	6 months → then yearly or 2–3 yearly depending on risk	Balance between early detection and over-medicalisation
BM re-biopsy	Only if progression suspected	Not routine in stable MGUS
Bone health	DXA, Vit D, Ca supplementation ± bisphosphonates for osteoporosis	MGUS ↑ fracture risk independent of lytic lesions
Infection prevention	Vaccinations (influenza, pneumococcal, COVID)	Immunoparesis → ↑ infection risk
VTE awareness	Patient education; peri-operative prophylaxis	~2× ↑ VTE risk
Patient education	Explain condition, reassure, outline red flags	Reduce anxiety; ensure early presentation if symptoms develop

High Yield Summary — MGUS Management

"Management: monitoring only" ^[2] — no chemotherapy, no immunotherapy for MGUS itself.
"Only multiple myeloma patients will be symptomatic with organ involvement → requires treatment. Other forms do not require treatment → require monitoring." ^[3]
Risk stratification uses the Mayo Clinic 3-factor model: M-protein ≥ 1.5 g/dL, non-IgG isotype, abnormal sFLC ratio.
Surveillance: SPEP, sFLC ratio, CBC, calcium, creatinine — at 6 months, then annually or 2–3 yearly depending on risk group.
Rate of rise in paraprotein is a key monitoring parameter ^[1]^[3] — a rapid rise warrants expedited workup including BM biopsy and imaging.
Associated risk management: bone health (DXA, Vit D), infection prevention (vaccinations), VTE awareness.
Exceptions where clone-directed treatment IS indicated despite MGUS-level tumour burden: MGRS (renal damage from M-protein), AL amyloidosis (organ deposition), and IgM MGUS with symptomatic anti-MAG neuropathy.
If MGUS progresses to active MM: triple therapy (proteasome inhibitor + IMiD + dexamethasone) ± autologous HSCT ^[5].
Bisphosphonates are NOT routinely used in MGUS — only if coexisting osteoporosis. For patients with CKD (eGFR < 35): denosumab instead of IV bisphosphonates ^[19].
Patient education is crucial: reassure (not cancer), explain monitoring plan, and teach red-flag symptoms for urgent return.

Active Recall - Management of MGUS

References

Complications of MGUS

Before listing complications, it is important to understand a key distinction. MGUS is, by definition, a condition without end-organ damage. So when we talk about "complications of MGUS," we are really discussing two categories:

Complications arising from the monoclonal protein itself — even though the clone is small and does not meet criteria for malignancy, the circulating M-protein (or its free light chains) can still exert biological effects on various organ systems
The risk of malignant transformation — MGUS is a premalignant state, and progression to a frank haematological malignancy is the most feared long-term complication

Think of MGUS as a dormant volcano. It is not erupting (no CRAB damage), but the thermal vents (the M-protein) can still cause local effects, and there is always the risk that the volcano wakes up.

1. Malignant Transformation — The Most Important Complication

This is the complication that defines the entire management strategy of MGUS.

"Risk of progression of MGUS to myeloma is 1% per year" ^[3]

MGUS Subtype	Annual Progression Risk	What It Can Progress To
Non-IgM MGUS	0.8%/year ^[2]	MM, plasmacytoma, AL amyloidosis ^[2]
IgM MGUS	2%/year in first 10 years, then ~1%/year ^[2]	Waldenström macroglobulinaemia, AL amyloidosis, NHL, CLL ^[2]
LC-MGUS	0.3%/year ^[2]	Idiopathic Bence Jones proteinuria (LC-SMM), light chain MM ^[2]

At 25 years of follow-up, 25–30% of MGUS patients will have progressed ^[2]. However, because the median age of diagnosis is 65–70 years ^[2], many patients will die of other causes before progression occurs. This is why overall lifespan is only slightly reduced: 8.1 years vs 12.4 years in matched controls ^[2].

"MGUS (Asymptomatic) → SMM (Asymptomatic) → MM (Symptomatic) → Extramedullary MM / Plasma cell leukaemia" ^[7]

Risk factors for progression: ^[1]

Size of paraprotein — "Small, lower chance" ^[3]
Type of paraprotein — non-IgG types carry higher risk
Light chain ratio — "Approaching 100, poor prognostic marker" ^[3]
Rate of rise in paraprotein — "Rapid rise is alarming, require monitoring soon" ^[3]
Bone marrow morphology — "Ugly looking plasma cells, clinical course worse" ^[3]

High Yield — Past Paper Question (2023 Fourth Summative)

Question 44: "Ms. Chan is recently diagnosed IgG lambda MGUS. Her IgG level was 1900 mg/dL and other immunoglobulin levels were normal. Her paraprotein level was 5 g/L. Her other blood tests were normal. What is her MOST LIKELY prognosis?" ^[20]

The correct answer is B: She has 1% risk of progression into myeloma after one year of follow-up. Explanation:

Option A is wrong: the condition may not remain stable — MGUS always carries a progression risk, regardless of immunoparesis status.
Option B is correct: MGUS carries ~1% per year risk of progression ^[3].
Option C (10%/year) describes SMM, not MGUS.
Option D is wrong: not all IgG lambda MGUS patients develop amyloidosis — AL amyloidosis is a DDx to consider, but it is not inevitable.

This question directly tests whether you know the annual progression rate of MGUS (1%) vs SMM (10%).

Once a patient progresses to active MM, they develop the CRAB complications:

"HyperCalcaemia / Bone lesions: active osteoclasts ... Renal failure ... Anaemia (NcNc) / bleeding tendency: BM infiltration + acquired vWD" ^[5]

The key point is that these are complications of MM, not of MGUS itself. In MGUS, these features are by definition absent. Their development signals that the patient has left the MGUS state.

2. AL Amyloidosis

"AL amyloidosis is a DDx if patient has suggestive symptoms" ^[1]

This is arguably the most important "complication" of MGUS, though it is more accurately described as a disease that can arise from or coexist with an MGUS-level clone.

The clonal plasma cells produce monoclonal free light chains
Certain light chains (especially λ) have a propensity to misfold into β-pleated sheet structures (amyloid fibrils)
These fibrils deposit in tissues: heart, kidneys, nerves, liver, GI tract, soft tissues
The deposits are Congo red positive (apple-green birefringence under polarised light) and consist of non-branching fibrils on electron microscopy ^[18]
Crucially, AL amyloidosis can occur with a very small clone — the BM plasma cells may be < 10% and the M-protein < 3 g/dL

Organ	Manifestation	Mechanism
Heart	Restrictive cardiomyopathy, HFpEF, arrhythmias, conduction blocks	Amyloid fibrils infiltrate myocardium → stiff, non-compliant walls
Kidney	Nephrotic syndrome (heavy proteinuria, oedema)	Amyloid deposits in glomeruli → disruption of filtration barrier
Nerves	Peripheral sensorimotor neuropathy, autonomic neuropathy (postural hypotension, early satiety, constipation/diarrhoea)	Amyloid deposits in vasa nervorum and endoneurium
Soft tissue	Macroglossia, periorbital purpura, carpal tunnel syndrome	Direct amyloid infiltration of tongue, small vessels, flexor retinaculum
Liver	Hepatomegaly, elevated ALP	Sinusoidal and periportal amyloid deposition
GI tract	Malabsorption, GI bleeding	Mucosal/submucosal amyloid deposition

Non-IgM MGUS has an increased risk of AL amyloidosis ^[2]. The annual rate is included within the overall ~0.8%/year progression figure.

Why AL Amyloidosis Can Be Fatal Even With a Tiny Clone

Students sometimes think: "The clone is small (< 10% BM plasma cells), so it can't be dangerous." This is wrong. In AL amyloidosis, it is not the tumour burden that kills — it is the toxicity of the protein product. Even a small factory producing toxic waste can poison the whole neighbourhood. Untreated cardiac AL amyloidosis has a median survival of ~6 months. This is why the GC slide specifically states: "AL amyloidosis is a DDx if patient has suggestive symptoms" ^[1].

3. Infections and Immunoparesis

Even in MGUS, the clonal plasma cell population can suppress normal polyclonal immunoglobulin production — a phenomenon called immunoparesis. The mechanism involves:

Clonal dominance of the BM niche → crowding out normal plasma cell precursors
Immunoregulatory cytokines produced by the clone (e.g., TGF-β, IL-10) that suppress normal B-cell differentiation
The result is reduced levels of uninvolved (normal) immunoglobulins (e.g., in IgG MGUS: IgA and IgM may be suppressed)

"Recurrent infections: immunoparesis (↓↓ other Ig)" ^[5] — this is listed as a complication of MM, but immunoparesis begins even at the MGUS stage, just to a lesser degree.

MGUS patients have a ~2-fold increased risk of bacterial infections compared to age-matched controls
Particularly susceptible to encapsulated organisms (Streptococcus pneumoniae, Haemophilus influenzae) — because opsonisation requires intact antibody responses
"Due to ↓ opsonization of encapsulated organisms by Ig production" ^[16]
Risk is proportional to the degree of immunoparesis — more suppressed uninvolved Ig = higher infection risk

Pneumococcal and influenza vaccination recommended
Low threshold for investigating febrile episodes
Consider prophylactic antibiotics in patients with recurrent infections + severe immunoparesis (though this is more commonly applied in MM/SMM)

4. Osteoporosis and Fractures

MGUS patients have a 2–3× increased risk of fracture (particularly vertebral and hip) compared to age-matched controls, even in the absence of lytic bone lesions. Why?

Low-level osteoclast activation: Even a small clone produces cytokines (RANKL, DKK1, MIP-1α) that tip the bone remodelling balance toward resorption — not enough to cause lytic lesions, but enough to reduce BMD over years
Inhibition of osteoblasts: DKK1 (Dickkopf-1) produced by clonal plasma cells inhibits the Wnt signalling pathway that drives osteoblast differentiation → reduced bone formation
Age-related synergy: MGUS patients are elderly (median age 65–70) → already at risk for osteoporosis; the clonal contribution adds to this
Immunoparesis-related inflammation: chronic low-grade immune dysregulation → pro-inflammatory state → bone loss

Vertebral compression fractures
Hip fractures
Pathological fractures (these should raise suspicion for progression to MM with lytic lesions — differentiate carefully)

DXA scan for baseline BMD
Vitamin D and calcium supplementation
Bisphosphonates or denosumab if osteoporosis is confirmed by standard criteria (but NOT routine for MGUS alone without osteoporosis)

5. Venous Thromboembolism (VTE)

MGUS patients have approximately a 2× increased risk of DVT and PE. Several mechanisms contribute:

Paraprotein-mediated coagulation activation: M-proteins can interact with coagulation factors (e.g., acquired activated protein C resistance, anti-phospholipid antibody-like activity)
Endothelial dysfunction: low-level cytokine production from clonal cells → endothelial activation → prothrombotic state
Hyperviscosity (mild): even modest M-protein levels can slightly increase serum viscosity, slowing blood flow
Inflammatory milieu: chronic immune dysregulation → acute phase reactant elevation → procoagulant shift

DVT (lower limbs)
Pulmonary embolism
Risk is present throughout the course of MGUS, not just at diagnosis

No routine anticoagulation for MGUS (risk too low)
Appropriate VTE prophylaxis during hospitalisation, post-surgery, and periods of immobility
Patient education on VTE warning signs

6. Peripheral Neuropathy

Peripheral neuropathy occurs in approximately 5% of MGUS patients, and is most strongly associated with IgM MGUS.

The predominant mechanism in IgM MGUS is:

The IgM M-protein acts as an autoantibody against myelin-associated glycoprotein (MAG) — a protein on the surface of Schwann cells and myelin sheaths
Anti-MAG antibody binding → complement activation → demyelination → distal sensorimotor polyneuropathy
The neuropathy is typically slowly progressive, affecting distal lower limbs first, with prominent sensory ataxia and tremor

In non-IgM MGUS, neuropathy is less common and may involve:

Light chain deposition in vasa nervorum or endoneurium
Amyloid neuropathy (AL amyloidosis — see above)
POEMS-related neuropathy (associated with λ light chain)

Distal sensory loss (numbness, tingling, "glove and stocking")
Gait ataxia (loss of proprioception)
Weakness (later stages)
Autonomic dysfunction (if amyloid-related)

IgM anti-MAG neuropathy: rituximab (targets the IgM-producing B-cell/lymphoplasmacytic clone)
Amyloid neuropathy: treat the underlying clone
Symptomatic: gabapentin/pregabalin for neuropathic pain

"Myeloma (CRAB), Monoclonal gammopathy" is listed as a cause of CKD ^[4]

Pathophysiology

Even at MGUS-level tumour burden, the monoclonal protein can cause a spectrum of renal pathology — now termed Monoclonal Gammopathy of Renal Significance (MGRS):

Renal Lesion	Mechanism	Key Features
AL amyloidosis	Light chains misfold → amyloid fibrils deposit in glomeruli	Nephrotic syndrome, Congo red positive
Light chain deposition disease (LCDD)	Light chains deposit in basement membranes as granular, non-fibrillar deposits	Nodular glomerulosclerosis (mimics diabetic nephropathy), Congo red NEGATIVE
Light chain proximal tubulopathy	Light chains are toxic to proximal tubular cells → acquired Fanconi syndrome	Glycosuria, aminoaciduria, phosphaturia, low-molecular-weight proteinuria
Type I cryoglobulinaemic GN	Monoclonal Ig precipitates in cold → immune complex GN	Purpura, arthralgias, GN
Proliferative GN with monoclonal Ig deposits	Monoclonal Ig deposited in glomeruli triggering proliferative response	Haematuria, proteinuria, ↓ complement
C3 glomerulopathy	Monoclonal Ig acts as autoantibody against complement regulators (e.g., Factor H)	C3 deposits without Ig deposits

"Other renal diseases associated with monoclonal light chains: Amyloidosis (AL type), Light chain deposition disease, Light chain proximal tubulopathy, Type I cryoglobulinaemic glomerulonephritis" ^[12]

"Light and heavy chain deposition disease — complication of monoclonal gammopathy" ^[11]

MGRS — Why It Matters Clinically

If a patient labelled as "MGUS" develops unexplained proteinuria, haematuria, or rising creatinine, you must consider MGRS. The critical distinction: in true MGUS, the kidneys are normal. In MGRS, the clone is small but the protein is directly injuring the kidney. Renal biopsy is essential for diagnosis. Treatment is clone-directed (e.g., bortezomib-based), not just renal supportive care. Failure to recognise MGRS leads to progressive, irreversible renal damage.

This is not a "complication" in the traditional sense, but it is a clinically important consequence of having a circulating M-protein that can lead to misdiagnosis and inappropriate management.

"Laboratory artifacts: circulating M protein may interfere with other lab tests, e.g. spuriously low HDL-C level, high bilirubin level, altered inorganic phosphate level" ^[2]

Lab Test Affected	Direction of Error	Mechanism
Total calcium	Falsely ↑	"Apparent high Ca → due to high globulin; Ig may precipitate with PO₄, interfering with measurement" ^[6]. M-protein binds calcium → ↑ total Ca with normal ionised Ca
Inorganic phosphate	Variable	"Ig may precipitate with PO₄, interfering with measurement" ^[6]
HDL-cholesterol	Falsely ↓	M-protein interferes with homogeneous HDL-C assays
Bilirubin	Falsely ↑	Turbidity from high protein levels interferes with colorimetric assays
ESR	Markedly ↑	Rouleaux formation accelerates RBC sedimentation
Anion gap	Altered	IgG is cationic → ↓ anion gap; IgA may → ↑ anion gap

Clinical impact: Clinicians unfamiliar with these artifacts may launch unnecessary investigations (e.g., workup for hypercalcaemia, lipid abnormalities) when the results are simply interference from the paraprotein. Always check ionised calcium and consider M-protein interference when interpreting unusual biochemistry in MGUS patients.

Occasionally, MGUS is associated with dermatological conditions:

Scleromyxoedema (papular mucinosis): IgG λ MGUS associated with diffuse papular skin thickening from dermal mucin deposition
Pyoderma gangrenosum: associated with IgA MGUS
Xanthoma (plane xanthogranuloma): especially with IgG M-protein
Schnitzler syndrome: chronic urticarial rash + IgM MGUS + intermittent fever + bone/joint pain; rare but recognisable
IgG Lambda monoclonal gammopathy associated with skin lesions has been illustrated in dermatology teaching material ^[21]

An underappreciated but real complication:

Being told you have a "pre-cancer" can cause significant anxiety and psychological distress
Patients may experience health anxiety, fear of progression at every follow-up visit, and depression
Proper counselling and reassurance at diagnosis is essential (as discussed in the management section)

Complication	Frequency	Mechanism	Key Clinical Feature
Malignant transformation	~1%/year (overall)	Accumulation of genetic hits → SMM → MM/WM/lymphoma	Rising M-protein, new CRAB features
AL amyloidosis	Uncommon but lethal	Light chain misfolding → amyloid fibril organ deposition	Cardiomyopathy, nephrotic syndrome, neuropathy, macroglossia
Infections	↑ 2× vs controls	Immunoparesis → ↓ normal Ig → ↓ opsonisation	Recurrent bacterial infections (encapsulated organisms)
Osteoporosis/Fractures	↑ 2–3× vs controls	Low-level osteoclast activation + DKK1 osteoblast inhibition	Vertebral compression, hip fractures
VTE (DVT/PE)	↑ ~2× vs controls	Paraprotein-mediated coagulopathy, endothelial dysfunction	DVT, PE
Peripheral neuropathy	~5%	Anti-MAG antibodies (IgM MGUS); amyloid deposition; POEMS	Distal sensorimotor, ataxia
MGRS (renal)	Uncommon	M-protein/light chains directly damage kidney	Proteinuria, ↓ eGFR, various GN patterns
Lab interference	Common	M-protein interferes with biochemical assays	Factitious ↑Ca, ↓HDL, ↑bilirubin, altered anion gap
Skin disorders	Rare	Paraprotein deposition, immune-mediated	Scleromyxoedema, Schnitzler syndrome
Psychological distress	Common	Anxiety from "pre-cancer" label	Health anxiety, depression

High Yield Summary — Complications of MGUS

Malignant transformation is the most important complication: ~1% per year for non-IgM MGUS, ~2% per year for IgM MGUS ^[2]^[3]. Risk factors: size, type, FLC ratio, rate of rise of paraprotein, and BM morphology ^[1].
"AL amyloidosis is a DDx if patient has suggestive symptoms" ^[1] — can occur with an MGUS-level clone and is fatal if untreated (especially cardiac AL).
Immunoparesis causes increased susceptibility to encapsulated organisms — due to ↓ opsonization ^[16]. Vaccinations are recommended.
Osteoporosis and fractures are 2–3× more common even without lytic bone lesions — due to low-level osteoclast activation and DKK1-mediated osteoblast inhibition.
VTE risk is ~2× increased — paraprotein-mediated coagulopathy; no routine anticoagulation but ensure adequate peri-operative prophylaxis.
MGRS: small clone but direct renal toxicity from M-protein/light chains. Must biopsy kidney; requires clone-directed treatment.
Lab interference is common and clinically important: factitious hypercalcaemia (↑ total Ca, normal ionised Ca), spuriously low HDL-C, altered phosphate, high bilirubin ^[2]^[6]. Always check ionised calcium.
Past paper tested: MGUS has 1% per year risk of progression (not 10% — that is SMM) ^[20].

Active Recall - Complications of MGUS

References

^[1] Lecture slides: GC 030. An old man with bone pain and anaemia.pdf (MGUS slide) ^[2] Senior notes: Ryan Ho Haemtology.pdf (Section 3.6.2 Monoclonal Gammopathy of Undetermined Significance) ^[3] Senior notes: Block A - An old man with bone pain and anaemia_ multiple myeloma; monoclonal gammopathy.pdf (Development of myeloma / MGUS section) ^[4] Senior notes: Block A - Chronic Kidney Disease and its Complications.pdf (Causes of CKD) ^[5] Senior notes: Maksim Medicine Notes.pdf (Multiple myeloma clinical features, complications, immunoparesis) ^[6] Senior notes: Ryan Ho Chemical Path.pdf (Paraproteinaemia and factitious hypercalcaemia) ^[7] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (Spectrum of diseases for monoclonal gammopathy) ^[11] Senior notes: Block A – Nephrology Data Interpretation.pdf (Light and heavy chain deposition disease) ^[12] Senior notes: Block A - Nephrotology Teaching Clinic RTD.pdf (Renal diseases associated with monoclonal light chains) ^[16] Senior notes: Ryan Ho Haemtology.pdf (MM laboratory findings, immunoparesis mechanism) ^[18] Senior notes: Block A - Hematology Data Interpretation.pdf (Congo red stain, electron microscopy for amyloidosis) ^[20] Past papers: 2023 Fourth Summative MCQ.pdf (Question 44) ^[21] Lecture slides: Derm General Clerkship 2026 Part2.pdf (IgG Lambda monoclonal gammopathy with skin lesion)

High Yield Summary

MGUS is the most common plasma cell dyscrasia — ~5% of people > 50 years; M > F; prevalence ↑ with age
Definition: M-protein < 3 g/dL, BM plasma cells < 10%, no B-cell lymphoproliferative disorder, no end-organ damage (CRAB)
Three main subtypes: Non-IgM MGUS (most common, IgG > IgA), IgM MGUS (risk of WM/lymphoma), LC-MGUS
Progression risk: Non-IgM ~0.8%/year, IgM ~2%/year, LC ~0.3%/year
Risk factors for progression: Size of M-protein, type (non-IgG worse), abnormal FLC ratio, rate of rise, BM morphology
By definition asymptomatic — always an incidental finding; any CRAB symptom = exclude myeloma
Most important DDx to exclude: AL amyloidosis (especially if suggestive symptoms), MM, WM
Lab artifacts: Elevated ESR, reversed A:G ratio, factitious hypercalcaemia (check ionised Ca), interference with HDL-C, phosphate, bilirubin assays
Management: Monitoring only — no treatment; regular follow-up to detect progression
MGRS is a newer concept where the small clone causes direct renal damage → requires treatment despite not meeting MM criteria

High Yield Summary — Differential Diagnosis of MGUS

MGUS is a diagnosis of exclusion — you must systematically rule out MM, SMM, AL amyloidosis, WM, LCDD, POEMS, lymphoma/CLL, and MGRS before labelling a monoclonal gammopathy as "undetermined significance."
AL amyloidosis is the most important DDx if the patient has suggestive symptoms ^[1] — even with a small clone, light chains can cause fatal organ damage.
The distinction between MGUS, SMM, and MM is based on three parameters: M-protein level, BM plasma cell percentage, and presence of CRAB/MDE.
IgM MGUS is a distinct entity — the differential includes WM, NHL, and CLL (lymphoproliferative rather than plasma cell lineage).
The monoclonal gammopathy DDx table by isotype ^[7]: Non-IgM MGUS → SMM → MM; IgM MGUS → Smouldering WM → WM; LC-MGUS → Idiopathic Bence Jones proteinuria → LC-MM.
If a small clone causes organ damage (renal, cardiac, neurological), it is not MGUS — consider MGRS, AL amyloidosis, or LCDD.
An altered anion gap (reduced in IgG, increased in IgA gammopathy) can be a laboratory clue to underlying paraproteinaemia.

High Yield Summary — Diagnostic Criteria, Algorithm, and Investigations

MGUS diagnostic criteria (all must be met): M-protein < 3 g/dL; BM plasma cells < 10%; no B-cell lymphoproliferative disorder; no end-organ damage (CRAB/SLiM) ^[1]
CRAB = Calcium ↑, Renal insufficiency, Anaemia, Bone lesions. SLiM = Sixty % BM PC, Light chain ratio > 100, MRI > 1 focal lesion. Any CRAB or SLiM = active MM, not MGUS ^[5]
Investigation trio for monoclonal gammopathy screening: SPEP with immunofixation + serum FLC + 24h urine for BJP ^[5]
SPEP patterns: Normal / Pan-immunoparesis / Polyclonal ↑ (reactive, do NOT refer to haematology) / M-spike ± immunoparesis ^[15]
Normal κ:λ ratio = 0.26–1.65; abnormal suggests monoclonal origin ^[5]
BM biopsy is definitive: confirms < 10% clonal PC, provides morphology, immunophenotyping (CD138, light chain restriction), and cytogenetics for risk stratification
Skeletal imaging (WB low-dose CT preferred) must be normal in MGUS; ALP is usually normal in myeloma because osteoblastic activity is preserved ^[5]
Risk stratification: Mayo Clinic model uses M-protein ≥ 1.5, non-IgG isotype, abnormal FLC ratio → 0–3 risk factors determining surveillance intensity
Always exclude AL amyloidosis if any suggestive symptoms — even a small clone can produce lethal amyloid deposits ^[1]
Factitious hypercalcaemia: paraprotein binds calcium → ↑ total Ca with normal ionised Ca; check ionised Ca ^[6]

High Yield Summary — MGUS Management

"Management: monitoring only" ^[2] — no chemotherapy, no immunotherapy for MGUS itself.
"Only multiple myeloma patients will be symptomatic with organ involvement → requires treatment. Other forms do not require treatment → require monitoring." ^[3]
Risk stratification uses the Mayo Clinic 3-factor model: M-protein ≥ 1.5 g/dL, non-IgG isotype, abnormal sFLC ratio.
Surveillance: SPEP, sFLC ratio, CBC, calcium, creatinine — at 6 months, then annually or 2–3 yearly depending on risk group.
Rate of rise in paraprotein is a key monitoring parameter ^[1]^[3] — a rapid rise warrants expedited workup including BM biopsy and imaging.
Associated risk management: bone health (DXA, Vit D), infection prevention (vaccinations), VTE awareness.
Exceptions where clone-directed treatment IS indicated despite MGUS-level tumour burden: MGRS (renal damage from M-protein), AL amyloidosis (organ deposition), and IgM MGUS with symptomatic anti-MAG neuropathy.
If MGUS progresses to active MM: triple therapy (proteasome inhibitor + IMiD + dexamethasone) ± autologous HSCT ^[5].
Bisphosphonates are NOT routinely used in MGUS — only if coexisting osteoporosis. For patients with CKD (eGFR < 35): denosumab instead of IV bisphosphonates ^[19].
Patient education is crucial: reassure (not cancer), explain monitoring plan, and teach red-flag symptoms for urgent return.

High Yield Summary — Complications of MGUS

Malignant transformation is the most important complication: ~1% per year for non-IgM MGUS, ~2% per year for IgM MGUS ^[2]^[3]. Risk factors: size, type, FLC ratio, rate of rise of paraprotein, and BM morphology ^[1].
"AL amyloidosis is a DDx if patient has suggestive symptoms" ^[1] — can occur with an MGUS-level clone and is fatal if untreated (especially cardiac AL).
Immunoparesis causes increased susceptibility to encapsulated organisms — due to ↓ opsonization ^[16]. Vaccinations are recommended.
Osteoporosis and fractures are 2–3× more common even without lytic bone lesions — due to low-level osteoclast activation and DKK1-mediated osteoblast inhibition.
VTE risk is ~2× increased — paraprotein-mediated coagulopathy; no routine anticoagulation but ensure adequate peri-operative prophylaxis.
MGRS: small clone but direct renal toxicity from M-protein/light chains. Must biopsy kidney; requires clone-directed treatment.
Lab interference is common and clinically important: factitious hypercalcaemia (↑ total Ca, normal ionised Ca), spuriously low HDL-C, altered phosphate, high bilirubin ^[2]^[6]. Always check ionised calcium.
Past paper tested: MGUS has 1% per year risk of progression (not 10% — that is SMM) ^[20].

Monoclonal Gammopathy Of Undetermined Significance (MGUS)

References

Monoclonal Gammopathy of Undetermined Significance (MGUS)

Formal Diagnostic Definition (IMWG Criteria)

2. Epidemiology

3. Anatomy and Function: The Plasma Cell and Immunoglobulin System

4. Aetiology and Risk Factors

5. Pathophysiology

6. Classification of MGUS

What Determines Progression?

8. Clinical Features

Active Recall - MGUS

Differential Diagnosis of MGUS

Complete Differential of Monoclonal Gammopathy

Axis 2: Conditions to Actively Exclude Before Labelling "MGUS"

Active Recall - Differential Diagnosis of MGUS

References

Diagnostic Criteria, Algorithm, and Investigations for MGUS

3. Investigation Modalities — Detailed Interpretation

4. Risk Stratification of Confirmed MGUS

Active Recall - Diagnostic Criteria, Algorithm, and Investigations for MGUS

References

Management of MGUS

3. Detailed Management Components

3.4 Addressing Associated Risks in MGUS Patients

4. What Happens If MGUS Progresses?

5. Special Situations in MGUS Management

Active Recall - Management of MGUS

References

Complications of MGUS

1. Malignant Transformation — The Most Important Complication

2. AL Amyloidosis

3. Infections and Immunoparesis

4. Osteoporosis and Fractures

5. Venous Thromboembolism (VTE)

6. Peripheral Neuropathy

Pathophysiology

Active Recall - Complications of MGUS

References

On this page

Monoclonal Gammopathy Of Undetermined Significance (MGUS)

1. Definition

2. Epidemiology

Prevalence

Demographics

Hong Kong Context

3. Anatomy and Function: The Plasma Cell and Immunoglobulin System

Normal B-cell to Plasma Cell Differentiation

Structure of Immunoglobulins

Free Light Chains (FLC)

4. Aetiology and Risk Factors

Why Does MGUS Occur?

Risk Factors for Developing MGUS

Risk Factors for Progression of MGUS → Myeloma

5. Pathophysiology

The Clonal Expansion

Common Cytogenetic Abnormalities in MGUS

Why MGUS Does NOT Cause Organ Damage

Paraprotein-Related Phenomena (Even in MGUS)

6. Classification of MGUS

6.1 Non-IgM MGUS (Most Common)

6.2 IgM MGUS

6.3 Light-Chain MGUS (LC-MGUS)

6.4 Biclonal MGUS

7. The Plasma Cell Dyscrasia Spectrum

8. Clinical Features

8.1 Symptoms

8.2 Signs

8.3 How MGUS is Typically Discovered

9. Associated Conditions and Clinical Significance Beyond Progression

10. Investigations for Suspected MGUS (Brief Overview — Full Workup in Next Section)

Active Recall - MGUS

References

Axis 1: Differential Diagnosis of a Monoclonal Gammopathy (M-Protein Detected)

Axis 2: Conditions to Actively Exclude Before Labelling "MGUS"

2.1 Multiple Myeloma (Most Critical to Exclude)

2.2 Smouldering Multiple Myeloma (SMM)

2.3 AL Amyloidosis

2.4 Waldenström Macroglobulinaemia (WM)

2.5 Light Chain Deposition Disease (LCDD)

2.6 MGRS (Monoclonal Gammopathy of Renal Significance)

2.7 Lymphoma / CLL

2.8 POEMS Syndrome

2.9 Reactive / Transient Monoclonal Gammopathy

Classification Table for Differential Diagnosis by MGUS Subtype

The Practical Clinical Approach: "Is This Really Just MGUS?"

The Anion Gap Clue

Summary Differential Diagnosis Algorithm

Active Recall - Differential Diagnosis of MGUS

1. Diagnostic Criteria — IMWG Definition

Comparison Table: MGUS vs SMM vs Active MM

CRAB and SLiM — The End-Organ Damage and Biomarker Criteria

2. Diagnostic Algorithm

3. Investigation Modalities — Detailed Interpretation

3.1 Serum Protein Electrophoresis (SPEP)

3.2 Immunofixation Electrophoresis (IFE)

3.3 Serum Free Light Chains (sFLC) and κ:λ Ratio

3.4 24-Hour Urine Studies

3.5 Complete Blood Count and Peripheral Blood Smear

3.6 Biochemistry Panel

3.7 Bone Marrow Biopsy (Aspirate + Trephine)

3.8 Skeletal Imaging

3.9 Additional Investigations to Exclude AL Amyloidosis

3.10 Pre-Treatment Baseline Investigations (If Progression Suspected)

4. Risk Stratification of Confirmed MGUS

Mayo Clinic Risk Stratification Model (2005)

Follow-Up Surveillance Protocol

5. Summary Investigation Table for MGUS Workup

Active Recall - Diagnostic Criteria, Algorithm, and Investigations for MGUS

1. The Fundamental Principle

2. Management Algorithm

3. Detailed Management Components

3.1 Risk Stratification (Already Covered — Brief Recap)

3.2 Surveillance Protocol — What to Monitor and Why

3.3 Bone Marrow Re-Biopsy — When Is It Indicated?

3.4 Addressing Associated Risks in MGUS Patients

3.4.1 Bone Health

3.4.2 Infection Prevention

3.4.3 Venous Thromboembolism (VTE) Awareness

3.4.4 Renal Surveillance